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ABSTRACT 
The Retinoblastoma binding protein 6 is dysregulated in most cancers, indicating it 
may play a role in metabolic reprograming- a hallmark of carcinogenesis. Its human 
isoforms have been shown to play diverse roles in apoptosis. This study aimed to 
elucidate biochemical roles of RBBP6 isoforms in metabolic reprogramming during 
carcinogenesis. Drosophila melanogaster wild type and p53 null mutants were 
treated with drug permutations of irinotecan (DNA damaging agent) and exogenous 
pyruvate to perturb metabolism. Moreover,  using RT-PCR and Western blot 
expression profiles of  SNAMA (Drosophila Orthologue of RBBP6) isoforms were 
shown followed by survival studies to investigate the  effects of these drugs. 
Furthermore, using bioinformatics the domains of RBBP6 isoforms in various 
species were shown. Results indicate that RBBP6 isoforms show contrasting 
expression patterns. Furthermore, exogenous pyruvate protects the wild type flies 
from irinotecan toxicity while killing p53 null mutants. RBBP6 proves to be a 
potential druggable target for chemotherapy. 
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QUOTATION 
 
 
 
 
 
 
Knowledge can be communicated but not wisdom. One can find it, live it, be 
fortified by it, do wonders through it, but one cannot communicate and teach it. 
Hermann Hesse. 
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CHAPTER 1: INTRODUCTION 
1.1 Cancer & Carcinogenesis: An overview 
Cancer has been identified as one of the major health problems worldwide affecting 
individuals of every age (World Health Organization, 2015). There are variations 
between age of onset, growth rate and invasiveness. Globally, it kills more people 
than Malaria, AIDS, and Tuberculosis combined making it an urgent health 
problem. Cancer results when genetically damaged cells start proliferating 
uncontrollably. All cancers are due to abnormal cell proliferation, most of which is 
associated with aberrant cell cycle progression. Thus, damaged cells divide rapidly 
with their mutations bypassing the physiological checks and balances to prevent 
propagation of mutations (Hanahan and Weinberg, 2011). 
Risk factors of cancer formation include: environmental influences such as, 
radiation and exposure to ultraviolet light. These factors yield mutagens that alter 
the DNA and present pyrimidine dimers, single and double strand breaks. Lifestyle 
factors such as lack of exercise, unhealthy diet, excessive alcohol consumption and 
smoking also increase risk of cancer. However, most of the recorded cancer cases 
arise from inherited genetic mutations (www.cancer.net). Epigenetics also plays a 
huge role in cancer formation where tumour suppressor genes become silenced by 
epigenetic factors like the hyper-methylation of CpG islands (Fearon, 1997; Haber 
and Harlow, 1997). 
Cancer is the leading cause of death worldwide with approximately 14 million new 
cases recorded in 2012 (Ferlay et al., 2012). In 2015, there were 8.8 million cancer- 
related deaths globally. The world health organization estimates that within the next 
20 years the number of new cancer cases will increase by 70% (World Health 
Organization, 2015). According to global cancer statistics, men had a higher 
incidence of cancer in 2012. In South Africa, one in four individuals is affected by 
cancer and over 100 000 people are diagnosed annually with a survival rate of only 
60% (Cancer Association of South Africa, 2013). 
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When normal cells become diseased or damaged, they undergo a process called 
apoptosis (programmed cell death) whereby proliferation of these cells is curbed by 
induction of a genetically controlled death programme. On the other hand, cancer 
cells lack this ability and continue proliferating resulting in tumour growth. There 
are two types of tumours; benign and malignant tumours. Benign tumours are non-
cancerous but can still cause problems when they grow and exert pressure on crucial 
organs, like lungs where they make breathing difficult. Malignant tumours are able 
to spread from their original environment (metastasis) and move to other parts of 
the body (invasion) which can be life threatening.  
Carcinogenesis is a process where normal cells accumulate mutations and no longer 
respond to regulatory signals leading to an increase in abnormal cell proliferation. 
It consists of three major phases namely initiation, promotion and progression. 
During initiation, cells get exposed to carcinogens, causing changes to occur in a 
spontaneous manner, and further results in mutations in the cellular genome. The 
initiation phase is the major step of neoplasms (unusual growth of tissues). The 
mutated cell remains harmless until stimulated to continue dividing and cause cell 
imbalance. This stimulation occurs during the promotion phase (Devi, 2004). 
During the progression phase, neoplastic conversion occurs, this is when pre- 
neoplastic cells commit themselves to develop as malignant tumours. This is made 
possible by gene mutations accumulating inside the growing pre-neoplastic cell 
clone. Consequently, changes in the neoplasm produce a number of malignant cells 
continuously (World Health Organization, 2015). Most cancers are diagnosed late 
and by the time treatment is initiated, the cancer has spread to other organs. If most 
cancers could be diagnosed early, it would be easy to treat them and the chances of 
curing them would increase significantly. 
 
1.2 The use of irinotecan as a chemotherapeutic agent 
Chemotherapy is the treatment of cancer using drugs to destroy cancer cells. Most 
cancer patients depend on chemotherapy. However, adverse side effects are 
frequent and include nausea, vomiting, hair loss, abdominal pains, and infections. 
Almost all chemotherapeutic drugs do not discriminate between cancer and normal 
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cells resulting in these side-effects. For example, patients undergoing chemotherapy 
lose hair, stem cells and intestinal muco-epithelial cells because they are highly 
proliferative and sensitive to anticancer drugs. 
Camptothecin- a cytotoxic alkaloid first extracted from the Chinese tree 
Camptotheca acuminate was used widely as a chemotherapy drug before it was 
discontinued due to its adverse effects such as enteritis and cystitis (Schulz et al., 
2009). Furthermore, it was also found to be insoluble in aqueous solution, thus its 
semi-synthetic version; Irinotecan (CPT-11) was developed (Schulz et al., 2009). 
Irinotecan is soluble in water and is associated with less severe side effects in 
comparison to Camptothecin. 
Irinotecan is a DNA Topoisomerase I inhibitor that targets the rapidly dividing 
cancer during DNA replication (Liu et al., 2000). It is used for treatment of solid 
tumours such as breast, lung and colorectal cancer. Its mechanism of action 
involves the interaction with the enzyme topoisomerase 1. Topoisomerase 1 is an 
enzyme responsible for introducing temporary single strand breaks in the DNA 
during replication and then re-annealing them in a new confirmation, thereby 
relaxing the DNA supercoils. Irinotecan binds to topoisomerase 1-DNA complex 
and inhibits religation of the DNA strand, as a result lethal double strand, replication 
arrest and apoptosis occurs as shown in figure 1.1. 
 
Figure 1.1: Irinotecan mechanism of action. Irinotecan binds to topoisomerase 1- DNA 
complex, formation of this complex inhibits religation of DNA strand, further resulting in 
replication arrest, lethal double strand breaks and apoptosis. This figure was created using 
Microsoft® PowerPoint. 
Irinotecan
Replication	arrest
Lethal	double	stranded	breaks
DNA	damage	not	repaired
Apoptosis
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Topoisomerase 1 is very important in Drosophila melanogaster development, it is 
found in increased quantities within developing embryos (Lee et al., 1993).  A study 
by (Thomas et al., 2013) showed that most Drosophila stocks carry mutations in 
Cyp6d2 which make them hypersensitive to Camptothecin and its analogues. 
Irinotecan is a DNA damaging agent and it’s used in this study as such (Takeba et 
al., 2007). 
 
1.3 Cellular metabolism in carcinogenesis 
Cellular metabolism refers to the total biochemical processes that take place in 
living organisms either utilization or generation of energy. Modifications to these 
processes can be observed during carcinogenesis and aid in propagating cancer cell 
growth (Hanahan and Weinberg, 2011). All cells require energy and nutrients to 
grow and to proliferate. Glucose is the primary energy source for cells and is crucial 
throughout its life cycle. Most normal cells metabolise their glucose using the 
mitochondrial Oxidative phosphorylation (OXPHOS) which is more efficient than 
glycolysis. It gives rise to a net total of 36 ATP molecules compared to two 
molecules produced by glycolysis.  
1.3.1 Glycolysis 
Glycolysis is the primary metabolic pathway used by all organisms to breakdown 
glucose for energy production and it occurs in the cytoplasm. Glycolysis is a 
multistep process that involves the initial step of breaking down a six-carbon 
glucose molecule to two-carbon molecules of glyceraldehyde-3-phosphate and 
finally the formation of two pyruvate molecules that get oxidized under anaerobic 
conditions (Figure 1.2). NAD+ molecules get reduced to NADH and two ATP 
molecules are produced in the process. The glycolysis pathway can be halted when 
all NAD+ is converted to NADH. However, more NADH gets reconverted to NAD+ 
when pyruvate is converted to lactate by the enzyme lactate dehydrogenase.  
 P53 controls glycolysis at multiple points such as directly repressing the expression 
of glucose transporters (GLUT 1 and GLUT 4) as well as GLUT 3 indirectly (see 
section 1.5).  
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1.3.2 Citric acid cycle/ tricarboxylic cycle 
The citric cycle takes place in the mitochondria under aerobic conditions. The end 
product of glycolysis, pyruvate, enters the mitochondrion to be fully oxidized to 
acetyl-CoA, releasing one molecule of CO2 facilitated by the enzyme pyruvate 
dehydrogenase. Acetyl-CoA enters the citric acid cycle and releases another two 
CO2 molecules. High energy carriers bounce off from the citric acid cycle as acetyl 
CoA goes through the cycle. 
1.3.3 Oxidative Phosphorylation 
Oxidative phosphorylation (OXPHOS) also known as the electron transport chain 
takes place in the mitochondrion. It is responsible for synthesizing approximately 
90% of total 36 ATP molecules in the cell. During the tricarboxylic cycle, NADH 
and FADH2 are formed and then re-oxidized by mitochondrial membrane enzyme 
complexes which pass electrons from these oxidized molecules to an electron 
acceptor; oxygen (O2), which is converted to H2O. The energy that is released from 
this cycle drives the synthesis of ATP through ADP, Pi, and mitochondrial enzyme 
complexes. During this process, an increase in mitochondrial membrane potential 
occurs due to many apoptotic signals released in the cytoplasm. In addition, 
increased reactive oxygen species (ROS) production leads to oxidative stress and 
the release of pro-apoptotic factors such as cytochrome c,  caspases and procaspases  
which further initiate apoptosis (Fleury et al., 2002).  
 
Figure 1.2: Metabolic pathway from glycolysis to OXPHOS. Glycolysis occurs in the 
cytoplasm and yields a net total of 2 ATP molecules. The citric cycle is the only cyclic 
pathway  and takes place in the mitochondrion similarly to OXPHOS which produces a net 
total of 36 ATPs. Normal cells prefer this pathway. This figure was generated using 
Microsoft® PowerPoint. 
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1.3.4 The Warburg effect 
Otto Warburg discovered that cancer cells prefer to metabolise glucose using the 
inefficient glycolysis pathway regardless of the abundant oxygen in the 
environment. This preference is known as the “Warburg effect” (Warburg, 1956). 
Thus, cancer cells rely on glycolysis as the main source of energy generation even 
in aerobic conditions. This is referred to as aerobic glycolysis and enables cancer 
cells to carry on malignant progression (Bensaad and Vousden, 2007). It is 
hypothesized that the major reason cancer cells prefer glycolysis to OXPHOS is 
because it generates ATP faster even though it yields less energy compared to 
OXPHOS. Also, cancer cells are sensitive to the apoptotic effect of intracellular 
reactive oxygen species (ROS) caused by oxidative stress in the mitochondrion. It 
is hypothesized in this thesis that reversal of this phenomenon by boosting 
OXPHOS might aid in inducing cell death in cancer cells thereby inhibiting growth 
of cancer cells. Moreover, this might enhance the growth of normal cells.  
Apart from the Warburg effect there is also glutamine addiction where cancer cells 
become addicted to glutamine. In the 1950s, Harry Eagle studied the cell’s 
nutritional requirements and discovered that cancer cells consume glutamine more 
than any other amino acid and that absence of exogenous glutamine results in cell 
dormancy further affecting cell viability (Eagle, 1955). Additionally, when cancer 
cells are starved of glutamine they become vulnerable since it is recognized as the 
primary mitochondrial substrate required for the maintenance of mitochondrial 
membrane potential (Wise and Thompson, 2010). This further indicates the 
tendency of cancer cells to reprogram their metabolism, thus, this presents a 
potentially effective therapeutic target. 
 
1.4 Circumventing metabolic reprogramming: the role of Methyl 
pyruvate 
Metabolic reprogramming occurs when cancer cells alter their normal metabolic 
properties to sustain themselves as they require rapid energy production to support 
their fast proliferation. The end-product of glycolysis (preferred energy generation 
pathway of cancer cells) is pyruvate and providing this substrate exogenously to 
cells might enable them to circumvent this pathway and thus leading to their death. 
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In this study, 3-Methyl pyruvate (MP), a derivative of pyruvate was administered 
to bypass the glycolytic pathway. Methyl pyruvate is lipophilic in nature, making it 
more membrane permeable and stable than pyruvate. These two aforementioned 
characteristics enable it to be more favoured by the TCA cycle than pyruvate 
(Nishida et al., 2014). Furthermore, when introduced into cells exogenously it 
boosts OXPHOS and obstructs the Warburg effect. As a result cancer cells are killed 
and normal cells survive. Since glycolysis is enhanced during carcinogenesis, the 
use of methyl pyruvate to stimulate OXPHOS which generates mitochondrial 
reactive oxygen species may be used for cancer therapy (Monchusi and Ntwasa, 
2017).  
 
1.5 Mammalian and Drosophila melanogaster p53: Overview 
p53 is a tumour suppressor gene that encodes the protein product p53. It functions 
as a transcription factor that represses or stimulates the transcription of more than 
50 distinct genes. Human p53 is a member of the super family of proteins that 
consists of the tumour suppressors Tp53, Tp63 and Tp73. It is the most frequently 
mutated gene in human cancers occurring in more than 50% of all cases.  
In this study, Drosophila melanogaster is used as a model. Its p53 (Dmp53) null 
mutants are representative of some cancer genotypes. Human and Drosophila p53 
share similar structural and functional characteristics. For example, Dmp53 is 
involved in cell cycle arrest in response to DNA damage (Steller, 2000) by 
interacting with genes such as: p21, E2F, ATM, Rb, and cyclin-dependant kinases- 
which are found both in humans and Drosophila melanogaster to mediate this 
process.  
During cellular stress such as DNA damage, p53 is activated leading to an induction 
of a wide range of cellular response mechanisms which inhibit tumour development 
or repair the damaged DNA or induces apoptosis (Vogelstein et al., 2000; Vousden, 
2006). DNA damage brings about p53 activation which promotes cell cycle arrest 
and transactivation of repairing enzymes. If DNA damage cannot be repaired, then 
apoptosis occurs (Riley et al., 2008).  
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Apoptosis in Drosophila melanogaster 
In Drosophila melanogaster, apoptosis is crucial during embryogenesis. The 
induction of apoptosis involves the activation of three genes: reaper (rpr), head 
involution defective (hid) and grim (Mather et al., 2005). Reaper is an important 
effector of p53 induced apoptosis following DNA damage. It can be 
transcriptionally activated by a host of death inducing signals (Rodriguez et al., 
1998). Reaper targets Dmp53 (White et al., 1994) and  binds to the Drosophila 
inhibitor of apoptosis (DIAPI) which is capable of inhibiting Drosophila caspase 
activation. This activation is followed by the cleavage of ICAD (inhibitor of caspase 
deoxyribonuclease) to release free CAD by caspase 3, thereby stimulating apoptosis 
(Steller, 2000). When the three genes (rpr, hid, and grim) are expressed and 
functional, apoptosis is induced. When they are non-functional, it is inhibited 
(Grether et al., 1995; White et al., 1994).    
Apart from p53 mediated apoptosis there are other forms of cell death occurring in 
cells that are p53 independent. This is important as this study utilized p53 null 
mutant Drosophila models to assess survival when toxicity was induced. One of 
such cell death mechanism is Parthanatos. Cell death by Parthanatos differs from 
processes like apoptosis and necrosis. It depends mainly on poly ADP-ribose-
polymerase (PARP) activity, an enzyme that plays a role in the detection and 
initiation of immediate cellular response to metabolic, chemical or radiation 
induced single strand breaks. DNA damage or specifically single strand breaks 
causes the over activation of PARP which depletes cellular NAD+. NAD+ is a 
required substrate for ADP-ribose monomer production, its depletion further 
reduces cellular ATP to repair the damaged DNA. The depletion of ATP in the cell 
results in cell lysis and death. In addition PARP also possesses an ability to induce 
programmed cell death through the production of Poly (ADP-ribose)(PAR) which 
stimulates the release of apoptosis inducing factors(AIF) by the mitochondria 
(Fatokun et al., 2014). 
1.5.1 P53 Domains & Structure 
P53 has a molecular weight of approximately 53 kDa and is expressed as a tetramer 
protein in vivo. It has three domains, namely: the transactivational, DNA binding 
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and the tetramerization domains (Figure 1.3). The transactivational and DNA 
binding domains are located on the N-terminus of the p53 gene while the 
tetramerization domain is located on the C-terminus. The transactivational domain 
plays a crucial role in binding the protein Mdm2 (negative regulator of p53) in 
mammals. The MDM2 homologue is present in several vertebrates and 
invertebrates, however it hasn’t been identified in Drosophila melanogaster.  
The DNA binding domain interacts with DNA directly by folding into a β sheet 
which further forms a scaffold for a large loop and helix motif. This domain 
contains mutation hot spots. Over 80% of cancer-causing p53 mutations are found 
on this domain (Petitjean et al., 2007). Mutated p53 is defective when it comes to 
binding DNA and thus transactivation is inhibited which leads to the inability to 
suppress cancer cell growth as a result increased tumour formation occurs 
(Pietenpol et al., 1994). The tetramerization domain is responsible for 
oligomerization of p53 subunits. 
 
Figure 1.3: p53 domains with amino acid position. P53 comprises of three active 
domains known as the transactivation, DNA binding and the tetramerization domains. 
Adapted from (Ruttkay-Nedecky et al.,2013). 
 
During low glucose levels, the survival of normal cells depends on the p53 
activation pathway which induces the transcription of genes responsible for cell 
cycle arrest and DNA repair. The loss or mutations in p53 causes the protein to lose 
its ability to bind to its target DNA sequence and inhibit transcriptional activation 
of genes. Furthermore, these mutations alter the expression of important metabolic 
Transactivation Tetramerization
Sequence-specific DNAbinding
Non-specific
DNAbinding
Amino acid 98-292
P53 domains
363 - 39363 - 97 324 - 3551 - 50
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enzymes, inhibit oxidative phosphorylation (leading to the Warburg effect)  as well 
as oncogene activation (Pelicano et al., 2006). 
The regulation of the cell cycle occurs via two pathways, depending on the stress 
levels of the cell. Under mild stress conditions low p53 is enough to induce the 
transcription of genes responsible for cell cycle arrest (p21WAF1/ CIP1), DNA repair 
(P53R2) as well as those responsible for protection against oxidative stress 
(TIGAR, Sestrins, GPX1 and ALDH4) (Bensaad and Vousden, 2007). When genes 
responsible for protection against oxidative stress are induced, decreased levels of 
intracellular ROS is observed. However, when there is elevated stress, increased 
p53 levels induce the transcription of pro-oxidant genes (PIG3, Proline oxidase) 
and repress the transcription of antioxidant genes (PGM, NQO1). This reaction 
leads to an increased intracellular ROS levels and eventually cell death occurs 
(Bensaad and Vousden, 2007). 
The synthesis of cytochrome c oxidase 2 (SCO2) is important in the regulation of 
mitochondrial respiration by p53. SCO2 functions in regulating the cytochrome c 
oxidase complex.  P53 induces the transcriptional expression of SCO2  and TIGAR 
(Tp53-induced glycolysis and apoptosis regulator) while repressing the expression 
of glucose transporter genes (GLUT1 and GLUT2) (Figure 1.4) (Bensaad et al., 
2006). The expression of SCO2 and TIGAR is sufficient to slow down glycolysis 
and boost OXPHOS even at low levels. When p53 stimulates the expression of 
TIGAR, the result is the reduction of fructose-2, 6-bisphosphate further lowering 
glycolysis and activating the pentose phosphate pathway (PPP) which helps in 
reducing cell death that may be stimulated by oxidative stress. Down-regulating the 
expression of phosphoglycerate mutase (PGM) which is part of the glycolytic 
pathway slows down glycolysis, suggesting that cells may be forced to go through 
OXPHOS and proliferation inhibited. 
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Figure 1.4: p53 regulation of glycolysis. P53 regulates mitochondrial respiration by 
blocking the expression of glucose transporter genes (GLUT1 and GLUT4) while 
stimulating TIGAR to inhibit cytoplasmic glycolysis and SCO2  to boost OXPHOS (Zheng, 
2012). 
 
Glucose metabolism in Drosophila melanogaster 
Most metabolic processes in Drosophila are similar to those that are found in 
humans. Drosophila has been used to elucidate important characteristics of 
metabolic control conserved through evolution, giving new perceptions on more 
complicated vertebrate systems (Baker and Thummel, 2007). Its organ systems 
involved in uptake, storage, nutrient control, and metabolism are like those found 
in humans and other vertebrate species. For instance, the Drosophila fat body 
functions more like the mammalian liver and white adipose tissue. Also, the midgut 
of the Drosophila  which is analogous to the human stomach and intestines is 
responsible for the digestion and absorption of food (Baker and Thummel, 2007). 
Oenocytes function in accumulating lipids and upon starvation act like the human 
hepatocytes (liver cells) in processing lipids. For nutrient metabolism, Drosophila 
have developed a way to retain enough sugar levels in their systems. Excess sugar 
is stored in the form of glycogen which can be easily accessed when sugar depletion 
occurs or a need for energy arises (Rusten et al., 2004; Wigglesworth, 1949). 
Drosophila melanogaster has a glucose transport system similar to the one found 
in vertebrate species; although not much information was found on orthologues 
such as SCO2 and TIGAR which are very important in mammalian glucose 
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transport (Wang and Wang, 1993). More research focusing on SCO2 and TIGAR 
in Drosophila needs to be done. It will be important to know if the five GLUT 
receptors (GLUT1-5) found in mammals are also present in Drosophila 
melanogaster and if they have the same function. This study utilizes Drosophila as 
a model to further understand metabolism in cells. 
 
1.6 Mouse Double Minute 2 (Mdm2): a p53 Negative regulator. 
The Mdm2 gene was first identified on double chromosomes of spontaneously 
transformed mouse 3T3 fibroblasts and was later discovered to be associated with 
the tumour suppressor p53 (Cahilly-Snyder et al., 1987; Momand et al., 1992). 
MDM2 is a 90 kDa protein which binds p53  thereby regulating its expression (Chen 
et al., 1996; Finlay, 1993; Momand et al., 1992). Mdm2 exists in vertebrate species 
such as mouse, human, golden hamster and rat. Mdm2 homologs have also been 
discovered in invertebrates such as the deer tick and trichoplax. However, an Mdm2 
homologue in Drosophila melanogaster has not been identified. 
1.6.1 Mdm2 and p53 interaction 
There exists a negative feedback loop between Mdm2 and p53. Mdm2 is dependent 
on p53 binding to its promoter region to induce expression (Barak et al., 1993). An 
increase in Mdm2 expression is observed in normal cells, whereas there is a 
decrease during cellular stress such as DNA damage (Haupt et al., 2017). This 
increase in normal cells ensures p53 is kept at low levels. When this is the case, p53 
is un-phosphorylated consequently enabling the interaction of p53 and Mdm2 to 
form a complex (p53/Mdm2) resulting in p53 degradation in the proteasome 
through the ubiquitin pathway (Figure 1.5) (Haupt et al., 1997; Momand et al., 
1992). During DNA damage, p53 gets phosphorylated consequently inhibiting its 
binding to Mdm2. 
dRad6 and Dmp53 interaction 
In Drosophila melanogaster Dmp53 is regulated by the enzyme dRad6 which is 
found in humans as Rad6. It plays a role as a gene transcription regulator and an E2 
ligase responsible for repairing damaged DNA. dRad6 maintains the low levels of 
Dmp53 under stress-free conditions through ubiquitination and 26S proteasomal 
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degradation. It negatively regulates Dmp53 turnover by the formation of the 
Dmp53/dRad6 complex which results in degradation of Dmp53 (Dohmen et al., 
1991; Sung et al., 1991). Loss or mutations in the dRad6 inhibit Dmp53 
degradation, thus affects development and Drosophila morphogenesis (Chen et al., 
2011). 
 
Figure 1.5: Mechanisms of p53 regulation by Mdm2. Mdm2 regulates p53 at numerous 
levels. P53 and Mdm2 are connected through an autoregulatory negative feedback loop 
where p53 induces the expression of Mdm2 which in turn targets p53 for degradation. Also, 
stress signals like DNA damage phosphorylates p53 further interfering with complex 
formation and inhibiting p53 degradation. Source: (Moll and Petrenko, 2003). 
 
1.7 Retinoblastoma Binding Protein 6 and SNAMA structure 
The Retinoblastoma Binding Protein 6 (RBBP6) is a 250 kDa multiprotein located 
on human chromosome 16p22.2. RBBP6 plays a role in various biological 
processes such as translation, transcription, development as well as ubiquitination. 
The RBBP6 family is present in all eukaryotes but not in prokaryotes and is 
identified by several names: Human (RBBP6) Mouse (p53-associated cellular 
protein testes derived  PACT- or Proliferation potential-related protein -P2P-R), 
Drosophila melanogaster (SNAMA), C.elegans (RBPL-1) and Yeast (Mpe1p) 
which is involved in mRNA processing (Chen et al., 2013; Hull et al., 2015; Mather 
et al., 2005; Simons et al., 1997; Witte and Scott, 1997)Vo et al., 2001).   
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Most RBBP6 orthologues are negative regulators of p53. In mammals RBBP6 binds 
p53 and pRB tumour suppressors. It also promotes the degradation of p53 by 
enhancing Mdm2 activity (Sakai et al., 1995; Simons et al., 1997). However, 
SNAMA has not been shown to bind p53 although it has the p53-BD (p53 binding 
domain). Furthermore, SNAMA plays a role in apoptosis as well as in embryonic 
development (Mather et al., 2005). The mouse orthologue PACT is also a negative 
regulator of p53 and is crucial in development. Knock down of PACT results in 
early embryonic lethality just as loss of SNAMA leads to death of embryos (Li et 
al., 2007; Mather et al., 2005). RBBP6 and MDM2 share some structural and 
functional similarities.  
1.7.1 RBBP6 Domains 
The RBBP6 gene encodes a protein with multiple domains namely: Domain With 
No Name (DWNN), CCHC zinc finger, RING finger, Rb-binding domain, p53 
binding domain, Proline-rich, Serine- Arginine rich (S-R) and the Nuclear 
Localisation signal (Mather et al., 2005; UniProt, 2002) (Figure 1.6). The DWNN 
domain is located on the N-terminus in mammals and is present in all species. The 
C-terminus consists of (Proline rich region (337-349 residues), SR (679-773 
residues), Rb-binding (964-1120 residues) and p53-binding (1142-1727 residues 
(Simons et al., 1997; Witte and Scott, 1997). In Drosophila melanogaster SNAMA, 
a highly conserved N-terminal DWNN Catalytic Module (DCM) exists consisting 
of a ubiquitin-like domain DWNN, zinc finger motif as well as the RING finger-
like motif. Additionally, the C-terminus consists of  two lysine regions (Antunes, 
2009; Mather et al., 2005). 
The Domain with No Name (DWNN) 
The DWNN is common in all isoforms and is located on the N-terminus. In 
mammals, it  has a C-terminal GG motif which makes protease recognition possible 
and enables initiation of conjugation by cleaving between two glycine molecules 
(Pugh et al., 2006). In Drosophila melanogaster, the C-terminal GG motif is 
replaced by a proline rich region. The three dimensional structure of this domain 
has a ubiquitin-like fold and shares approximately 22% similarity with ubiquitin 
suggesting its involvement in the regulation of protein turn over in cells (Gao and 
Scott, 2002, 2003; Pretorius, 2007). 
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Zinc finger (CCHC type) and RING finger 
Zinc fingers are small proteins that bind to zinc atoms possessing finger-like 
protrusions that facilitate interaction with their target molecule. This makes zinc 
essential for domain stability (Krishna, 2003).  The CCHC zinc finger is the most 
common also known as the zinc knuckle and it possesses 40-60 amino acids (Miller 
et al., 1985). In Drosophila melanogaster almost all zinc fingers are involved in the 
development process and protein-protein synergy (Hart et al., 1996). The RING 
finger is a protein structural domain of zinc finger having an intrinsic E3 ubiquitin 
ligase which enable catalytic ubiquitin mediated proteasomal degradation of 
proteins like p53.  
Most proteins that possess the RING finger are involved in the ubiquitin pathway 
where they bind ubiquitination enzymes (E1 ubiquitin activating, E2 ubiquitin 
conjugating and E3 ubiquitin ligating enzymes) and their substrates (Lorick et al., 
1999). Firstly, ubiquitin is primed for action by an E1 ubiquitin activating enzyme, 
the activated ubiquitin is then transferred from E1 to E2 which acts as an escort for 
ubiquitin to its next destination- E3. E3 ubiquitin ligating enzymes are responsible 
for substrate recognition as well as promoting complex formations. Next, poly-
ubiquitin chain on protein is formed, then proteasome binds and removes the poly-
ubiquitin chain and unfolds protein which get degraded through a proteasome 
chamber (Joazeiro et al., 2000; Kappo et al., 2012). RING domains have conserved 
hydrophobic residues which are representative of the U-box domains, these are 
found in Drosophila isoforms (Figure 1.7). U box and RING domains are 
structurally similar and function as scaffolding molecules that recruit E2 in the 
ubiquitination pathway for degradation of proteins (Aravind et al., 2000). 
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Figure 1.6: RBBP6 human isoforms and the domains. All isoforms have a common 
DWNN domain while isoform 1, 2 and 4 have the zinc finger, RING finger, Rb binding 
domain and p53 binding domain in common. This figure was generated using Microsoft® 
PowerPoint. 
 
 
Figure 1.7: SNAMA domain structure. SNAMA A is the larger isoform and has the p53 
and Rb binding domains like in the human RBBP6, SNAMA B has the DWNN and zinc 
finger motif which enable it to carry out certain functions. This figure was generated using 
Microsoft® PowerPoint. 
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RBBP6 isoforms 
There are three RBBP6 isoforms in humans as shown in Table 1.1. They are derived 
from two mRNA transcripts, 1.1 and 6.1 kb. The 1.1 kb transcript encodes isoform 
3 and the 6.1 kb transcript encodes isoform 1, Furthermore, alternative splicing of 
the 6.1 kb transcript gives rise to isoform 2.  The length of Isoform 1 consists of 
1792 amino acids, 18 exons and has a size of 202 kDa. It  was shown to possess a 
ubiquitin ligase-like activity through its RING finger- domain by ubiquitinating 
YB-1 protein, thereby reducing its transactivational ability (Chibi et al., 2008). 
Isoform 1 is a full length isoform that binds both p53 and pRb (Sakai et al., 1995; 
Simons et al., 1997; Witte and Scott, 1997). It plays a pro-apoptotic role in human 
cancers. Isoform 2 is the second largest isoforms with an amino acid length of 1758, 
16 exons and a mass of 197 kDa. Isoform 3 is the shortest and comprises of only 
the DWNN domain. It has an amino acid length of 118, 3 exons and a mass of 13 
kDa (Di Giammartino et al., 2014; Dlamini et al., 2016; Simons et al., 1997). 
Isoform 3 is involved in the pro-apoptotic pathway in colon cancers also, it is 
speculated to compete with isoform 1 and 2 for binding sites.  
 
SNAMA isoforms 
SNAMA- Something that sticks like glue, is the name given to the Drosophila 
melanogaster homologue of RBBP6. It is located on chromosome 2 of the 
Drosophila genome and consists of two transcripts known as SNAMA A and 
SNAMA B (Figure 1.8). SNAMA A is the longest transcript and is 135 kDa,  has 
ten exons in total while the short isoform- SNAMA B is approximately 55 kDa and 
has seven exons (Table 1.2). The two Drosophila isoforms Snama A and B are 
similar to the human isoform one and three respectively. 
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Figure 1.8: Snama genomic structure. Schematic diagram showing Snama A and B 
translated and untranslated regions as well as the exons in them. The two transcripts have 
different untranslated regions and have some exons in common. Snama A has ten exons 
whereas Snama B only has seven. Adapted from (Hull et al., 2015). 
 
Table 1.1: Table depicting RBBP6 human isoforms, their lengths, molecular weight, 
exons and transcripts that code for the specific isoforms. 
 
 
Table 1.2: Table depicting Drosophila melanogaster SNAMA isoforms, their lengths, 
molecular weight, and exons.  
Isoform Amino Acid Length Mass (kDa) Exons 
SNAMA A 1231 135 10 
SNAMA B 494 55 7 
 
1.7.2 RBBP6 role in carcinogenesis 
The expression of RBBP6 is increased in most cancers such as lung, oesophageal, 
and colorectal making it a potential biomarker for these diseases. For example, it 
has been observed that RBBP6 is overexpressed in colon cancers and that this 
corresponds to metastasis signifying its role as a potential diagnostic and prognostic 
Isoform Amino Acid Length Mass (kDa) Transcript Exons 
1 1792 202 6.1 18 
2 1758 197 6.0 16 
3 118 13 1.1 3 
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biomarker (Ntwasa 2016; Chen 2013). Furthermore, its upregulation in multiple 
cancers makes it a good target for cancer therapy.  Additionally, RBBP6 is also 
implicated in the regulation of the cell cycle where its overexpression stimulate cell 
cycle arrest and  induces apoptosis (Gao and Scott, 2002). The short isoform 
comprising of just the DWNN domain is down regulated in human cancers while 
the longer isoforms are upregulated (Mbita et al., 2012). A down regulation of 
isoform 1 usually occurs with apoptosis while a down regulation of isoform 3 
coincides with carcinogenesis. In contrast, overexpression of isoform 3 inhibits 3 
end pre-mRNA cleavage in a similar way to siRNA-mediated knockdown of 
RBBP6 while overexpression of isoform 1 stimulate cell proliferation and leads to 
p53 degradation. The DWNN as a single module is also known to antagonize larger 
isoforms by competitive binding (Di Giammartino et al., 2014; Hull et al., 2015; 
Ntwasa, 2016). 
1.7.3 RBBP6 interaction with p53 
The human RBBP6 is an E3 ubiquitin-protein ligase which stimulates YBX1 
ubiquitination which results in its degradation by proteasome (Chibi et al., 2008). 
It binds with the tumour suppressor proteins pRB and p53 (Sakai et al., 1995; 
Simons et al., 1997; Witte and Scott, 1997), suggesting its role in carcinogenesis, 
cell cycle as well as apoptosis. RBBP6 interacts with p53 through the DNA binding 
domain where it negatively regulates p53. It facilitates this process by functioning 
as a scaffold protein to assist in the formation of the p53/Mdm2 complex. This then 
results in an increase of Mdm2 mediated ubiquitination and degradation of p53 by 
the proteasome (UniProt, 2002). 
SNAMA interaction with Dmp53 
Drosophila melanogaster p53 (Dmp53) is the homologue of TP53 (Human p53). It 
is a sequence specific DNA binding protein that plays a role in inducing apoptosis 
in Drosophila melanogaster (Ollmann et al., 2000a). The DNA binding domain of 
Dmp53 has been found to be similar to that of p53 in mammals thus making it a 
likely mutation hotspot (Ollmann et al., 2000b). 
Drosophila melanogaster p53 was isolated and cloned by three independent 
research groups. Their results showed that it was the only member of the p53 family 
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proteins in the fly (Mollereau and Ma, 2014) and it functions in a similar manner as 
the mammalian p53. For instance, in both mammalian p53 and Drosophila p53 the 
overexpression of the p53/Dmp53 induces apoptosis and the down regulation 
causes cells to be resistant to apoptosis. However, Dmp53 differs from p53 in that 
it does not induce a G1 cell cycle arrest and thus has no effect on the cycle (Ollmann 
et al., 2000a). 
It has been proposed in the past that there might be an interaction between SNAMA 
and Dmp53. SNAMA might function as a suppressor of apoptosis and possibly 
degrade apoptosis activators such as Dmp53 (Mather, 2006). SNAMA also plays a 
role in maintaining embryo development and regulating apoptosis (Mather et al., 
2005). The human RBBP6 and the mice homolog (PACT) play a crucial role in 
binding the non-mutated p53 and disrupt the p53 binding (Mather, 2006). 
The role of SNAMA in embryogenesis 
SNAMA plays an important role during the Drosophila melanogaster embryonic 
development. The deletion of SNAMA resulted in embryonic lethality, inhibition 
of cell cycle progression, and induction of abnormal apoptosis (Hull et al., 2015; 
Jones et al., 2006; Mather et al., 2005). Another role of SNAMA involves 
suppressing cell death for normal development in growing embryos (Hull et al., 
2015). SNAMA is differentially expressed throughout Drosophila development, 
where its expression is increased during embryogenesis and decreased in adult flies 
(Mather et al., 2005). The expression of SNAMA occurs on the periphery of the 
cellular blastoderm and not in the endoreplicating cells on the interior of the 
embryo. It is also involved in antero-posterior (A-P) embryonic patterning which is 
crucial for development (Hull et al., 2015).  
 
1.8 Drosophila melanogaster as a model for cancer studies 
Drosophila melanogaster also commonly known as the fruit fly has been previously 
used as a model in scientific research. It has the following advantages:  short life 
cycle of about ten days, production of many offspring, inexpensive and easy 
maintenance. It has four chromosomes and its genome consists of approximately 
14 000 genes.  
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It has been observed that 50% of proteins found in Drosophila have mammalian 
analogues and approximately 75% of existing human disease genes have 
Drosophila homologues. Furthermore, several models of human diseases and the 
best candidate genes linked to human diseases have been established in flies. 
Drosophila melanogaster has contributed to the understanding of fundamental 
biological mechanisms through the discovery of systems like the notch, toll and 
hippo signalling pathways. For example the hippo signalling pathway (a primary 
growth control pathway in vertebrates)  was discovered through studies with 
Drosophila tumour suppressor gene (Irvine and Staley, 2012). In this study the 
Drosophila melanogaster wild type and p53 null mutants were used to model 
normal cells and most cancers cells respectively. 
 
1.9 Justification of study 
Cancer is a global concern and kills more people than any other disease. It has major 
global economic impact costing billions of dollars annually for its management and 
treatment. This necessitates the development of new methods for treatment and 
management regimens. Targeting the metabolism of cancer cells provide a 
promising avenue to achieve this. Metabolic reprogramming has been identified as 
one of the hallmarks of cancer. Cancer cells prefer glycolysis (Warburg effect). 
P53 is highly mutated in cancers and has been linked to the induction of the 
Warburg effect.  RBBP6 and Mdm2 are E3 ubiquitin ligase proteins important for 
the negative regulation of p53 (Haupt et al., 1997; Li et al., 2007). They target the 
degradation of p53 through the ubiquitin pathway. While, interaction with p53 is 
known, the role of RBBP6 in metabolic reprogramming is not known. Targeting 
this interaction can help eradicate tumour cells (Chène, 2003). Understanding the 
role of RBBP6 during metabolic reprogramming may help identify targets. This 
study observes the expression of the RBBP6; mRNA and protein level for better 
understanding of their roles in metabolic reprogramming. 
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1.10 Aim 
The aim of this study was to evaluate the biochemical role of SNAMA isoforms in 
metabolic reprogramming. 
 
1.11 Objectives 
The objectives of this study comprised of the following: 
1. Comparing SNAMA isoforms to other invertebrates and vertebrates using 
sequence alignment tools. 
2. Gene expression profiling of Snama transcripts at various treatments 
(irinotecan, methyl pyruvate and a combination of both) using Reverse 
Transcriptase Polymerase Chain Reaction (RT-PCR). 
3. Protein expression profiling of SNAMA isoforms at various treatments 
using Western blot. 
4. Investigate the effects of the various treatments on survival using Kaplan 
Meier survival plots. 
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CHAPTER 2: MATERIALS AND METHODS 
2.1 Materials 
The materials used in this study are listed in the appendix section. Appendix A is 
comprised of laboratory equipment, manufacturer and model numbers of equipment 
(Table A1). Appendix B consists of the buffers and their compositions (Table A2). 
Appendix C, chemicals used as well as their supplier and catalogue numbers (Table 
A3). Appendix D consists of the aligned protein sequences for RBBP6 isoforms 
from different species. Appendix E comprise of survival analysis data. 
 
2.2 Overview of methods used 
In this chapter, methods utilized for this study are described. A bioinformatics study 
comparing RBBP6 isoforms in different vertebrate and invertebrate organisms was 
carried out. Sequences (FASTA format) were obtained from the National Centre of 
Bioinformatics Information (NCBI) and were aligned using Clustal Omega. 
Drosophila melanogaster was used as the model organism. The Drosophila strains 
used included; wild type Oregon R and p53 null mutant Psnama (Bloomington 
stock #6815 with a 3.3kb deletion at the p53 locus, y1 w1118; TI TI p53 5A-
1-4 and Psnama, p53/w;cyo;TM6B.They were treated with 0.1 µM of irinotecan, 
2.5% methyl pyruvate and a combination treatment of 5% methyl pyruvate and 0.1 
µM irinotecan. Various combinations of irinotecan and methyl pyruvate were used 
to induce DNA damage and perturb glucose metabolism respectively. Flies were 
treated by mixing the drug permutations with yeast in blobs which were placed in 
the vials for three days and then allowed to recover for a further nine days. Flies 
were harvested, counted and subjected to Trizol and sample buffer for RNA and 
protein extraction respectively at 3-day intervals. Total RNA and protein extraction 
were done followed by RT-PCR and Western blot analysis respectively. Bands 
were quantified using densitometry software myImageAnalysis version 2.0 
(Thermo Scientific) and statistical analysis was done using Microsoft® excel and 
GraphPad Prism 7 version 03. Statistix version 10 software was used to generate 
the Kaplan Meier survival plots following fly treatment. A summary of methods is 
shown in figure 2.1. 
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Figure 2.1: Flowchart showing experimental design for this research project. 
Bioinformatics analysis of RBBP6 isoforms was done to compare isoforms from different 
species. The Drosophila melanogaster wild type Oregon R and p53 null mutants (Psnama) 
were treated with irinotecan, methyl pyruvate and the combination treatment of both. RNA 
and protein were extracted, followed by RT-PCR, Western blot, and survival analysis.  
 
2.3 Bioinformatics analysis 
Protein sequences of the RBBP6 homologue isoforms of various species (Humans, 
Mice, Drosophila melanogaster and Caenorhabditis elegans) in FASTA format 
were obtained from the National Centre of Bioinformatics information (NCBI) 
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(https://www.ncbi.nlm.nih.gov). Sequences were then aligned using Clustal Omega 
(https://www.ebi.ac.uk).  
 
2.4 Drosophila melanogaster strains: rearing and treatment 
The Drosophila melanogaster strains – wild type Oregon R representing normal 
cells and the p53 null mutant flies (Psnama) representing a cancer phenotype were 
used. The Psnama mutants lack p53 but possess Snama, and phenotypically they 
can be identified with curly wings and red eyes. Flies were kept at 22ºC on a 12- 
hour cycle of lighting to ensure that all biological developments correspond to the 
time of day. Additionally, they were harboured in vials containing cornmeal agar 
and yeast as food supplement. For good health maintenance, flies were transferred 
to fresh vials on a weekly basis. Treatments administered comprised of 0.1 µM 
irinotecan, 2.5% methyl pyruvate as well as the combination of both (0.1 µM 
Irinotecan and 5% methyl pyruvate). 2.5% methyl pyruvate was used for individual 
treatment and 5% methyl pyruvate was used for the combination treatment. These 
concentrations were found to be optimal to perturb the metabolism in flies by (Hull 
et al., 2015). 
 
2.5 RNA Extraction 
Total RNA was isolated using the TRIzol method (Chomczynski, 1993). Trizol 
(500 µl) was added into 1.5 ml eppendorf tubes which had thirty flies and were 
crushed with sterilized homogenisers and incubated in ice for 5 mins. Following 
incubation, the homogenised sample was centrifuged at 12 000 rpm for 5 mins at 
4ºC to separate the constituents of the sample according to weight. 100 µl of 
chloroform was added into the previously centrifuged mixture and was shaken 
vigorously until it turned milky. This was then incubated in room temperature for 
10 mins after which it was centrifuged at 12 000 rpm for 15 mins at 4ºC. 
Subsequently, the top aqueous layer was carefully collected and placed into a fresh 
new eppendorf tube. 200 µl of isopropanol was then added to this aqueous solution 
and incubated at room temperature for 7 mins. Following incubation, centrifugation 
at 12 000 rpm for 10 mins at 4ºC was done and supernatant discarded. 200 µl of 
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cold 70% ethanol was added to the eppendorf tube and centrifuged at 12 000 rpm 
for 5 mins at 4ºC. The supernatant was then discarded and pellet left to air dry for 
7 mins.   To allow the pellet to dry properly, sample was placed in the heating block 
for 5 mins at 95°C. 50 µl of nuclease free water was added to pellet and tube placed 
in the heating block for 5 mins at 65ºC to allow dissolving. Afterwards, the sample 
was immediately incubated on ice for 10 mins. The Nanodrop® 1000 was used to 
determine the RNA concentration on all the samples. Absorbance at 260/280 was 
more than 1.8 in all samples. After RNA quantification, samples were stored at -
20°C until required. 
 
2.6 Reverse Transcription – Polymerase Chain Reaction 
cDNA synthesis was performed using the RevertAid First Strand cDNA synthesis 
Kit #K1622 according to the manufacturer’s protocol. About 2 µg of Total RNA 
was used across all samples. Samples were incubated for 60 mins at 42°C and the 
reaction terminated by heating at 70°C for 5 mins. 
PCR was performed following the manufacturer’s protocol provided on the PCR 
Mastermix booklet M0482S. Table 2.1 shows primers with specific sequences used 
for PCR. 
 
Table 2.1: Oligonucleotides/ Primers and sequences used in this study. 
PRIMERS  SEQUENCE 
 
Snama A fwd. 5ATCTGGACATCGTCGCTCTG 3 
Snama A rev. 5 CTTCTTCTGGCGATCCCCT 3 
Snama B fwd. 5 GATGCCTTGCAATCCTCAGC 3 
Snama B rev. 5 CAAAGTATGCCGAATATAGATTC 3 
RP49 fwd. 5 TGTTGTGTCCTTCCAGCTTCAA 3 
RP49 rev. 5 ACTGATATCCATCCAGATAATG 3 
 
After all reagents had been added, the PCR tubes were placed in the thermal cycler 
and the program was set as shown in Table 2.2. 
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Table 2.2: RT-PCR Cycle conditions including the steps followed, temperature and 
time. 
STEP TEMPERATURE TIME 
Initial Denaturation 95ºC 30 secs 
 
PCR cycles (30) 
95ºC 
45-68ºC 
68ºC 
15-30 secs 
15-60 secs 
1 min/kb 
Final Extension 68ºC 5 mins 
Hold 4ºC - 
 
2.7 Agarose gel electrophoresis 
1% Agarose gel was prepared by mixing an appropriate amount of agarose powder 
with 1X TBE.  The mixture was heated until the agarose had completely dissolved. 
6 µl of 10 mg/ml ethidium bromide was added to the mixture to allow for DNA to 
be visible in UV light. The mixture was then poured into a tray with a comb which 
created wells, and it was allowed to cool at room temperature. Afterwards, the comb 
was carefully removed and the gel was placed into the electrophoresis tank 
containing 1X TBE. A total of 12 µl comprising 10 µl sample and 2 µl 6X loading 
dye was loaded into each well. 6µl of the 1kb plus DNA gene ruler (Thermo 
Scientific) was loaded into the first well and samples in subsequent ones. The gel 
was run at 100 volts for approximately 30 mins to an hour and later visualised using 
the Chemidoc system (Bio-Rad). 
 
2.8 Protein Extraction 
Protein extraction was performed using sample buffer (Table A2 in appendix B for 
constituents). Thirty flies were placed in 1.5 ml eppendorf tubes and left in ice for 
5 mins. This was done in triplicates for wild type and duplicates for p53 null 
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mutants. 500 µl of sample buffer was then added and flies homogenised using 
plastic homogenisers. The homogenate was placed into a water bath at 95 ºC for 5 
mins. Afterwards, homogenate was centrifuged at 12 000 rpm for 5 mins which 
allowed for separation into 2 phases. The upper aqueous phase was collected and 
transferred into clean eppendorf tubes and stored at -20ºC until use. 
 
2.9 Protein Quantification. 
Protein quantification was done using the Bradford protein assay. Five dilutions of 
the protein standard were prepared and the solutions were assayed in duplicates. 
The concentrations of the protein standards were as follows: 10 µg/ml, 20 µg/ml, 
30 µg/ml, 40 µg/ml and 80 µg/ml. 160 µl of each sample solution, standard and 
blank were pipetted into separate microtiter plate wells. 40 µl of the dye reagent 
concentrate (Bio-Rad) was added into each well and the sample and reagent were 
mixed thoroughly using a pipette. Samples were incubated at room temperature for 
5 mins and the absorbance was measured at 595 nm using a spectrophotometer 
(Thermo Scientific). Absorbances were exported to Microsoft excel and samples 
subtracted from blank and concentration calculated. 
 
2.10 Sodium Dodecyl Sulphate-PAGE and Western Blotting 
SDS-PAGE was done according to the protocol designed by (Laemmli, 1970). The 
samples were placed on a dry bath for 5 mins at 95 ºC and 20 µl of the protein 
samples (crude extract) were loaded onto the gel. For separation, cellular proteins 
were separated according to size and length at 100 volts for 1 hr 30 mins.  
Following separation, proteins were transferred to PVDF membranes (Amersham 
Hybond-P) immersed in methanol, dH2O and Towbin buffer for calibration. 
Transferring of proteins took place in a semi-dry blotter (Hoefer VE) for 1 hr 30 
mins at constant current (280 mA). The membranes were then blocked with 
SuperBlock® protein blocking buffer (Thermo Scientific) for 1 hr at 4ºC to prevent 
non-specific binding of proteins. Three, 3 mins washes with 1 X PBS-Tween 
followed and membrane probed with a primary antibody (Table 2.3). The 
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membrane was washed five times in 1 X PBS-T for five mins per wash and then 
incubated at room temperature in an appropriate secondary antibody (Table 2.3) to 
specifically bind to the significant primary antibody for 1 hr. Five, 5 mins washes 
with 1 X PBS-T followed.  
Substrate (Western Bright™ Quantum, Western blotting detection kit (advansta K-
12042-D10)) was added to the membrane in a 1:1 ratio and incubated in the dark 
for 3 mins. The membrane was then analysed using the Bio-Rad imaging system. 
Table 2.3: Antibodies that were used in this study as well as the dilutions and the 
catalogue numbers. 
ANTIBODY DILUTION CATALOGUE NO. SUPPLIER 
pAB anti-RBBP6 
rabbit + polyclonal 
(primary) 
1:5000 NBP1-49535 Santa Cruz 
Biotechnology 
Anti-rabbit IgG 
peroxidase raised in 
rabbit (secondary) 
1:10 000  A-0545 Sigma 
β Tubulin Goat 
polyclonal IgG 
(primary) 
1:1000 K2206 Santa Cruz 
Biotechnology 
Anti - Goat IgG 
(Whole molecule) 
peroxidase raised in 
rabbit (secondary) 
1:2000 A8919 Sigma 
 
2.11 Statistical Analyses 
MyImageAnalysis version 2.0 (Thermo Scientific) was used for the quantification 
of both RT-PCR and Western blot bands. Their optical densities were exported to 
Microsoft Excel for normalisation, standard deviation, and mean calculation. Bar 
charts were generated using GraphPad Prism 7. version 03.  
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2.12 Survival Experiment 
Fly treatment and counting  
Twenty wild type (per group) and p53 null mutant flies of the same age were 
carefully distributed into separate labeled vials containing cornmeal and agar as 
food supplement. Five independent experiments were set up. The flies were 
exposed to various forms of treatments comprising; 0.1 M irinotecan, 2.5% methyl 
pyruvate only and 0.1 M Irinotecan + 5% methyl pyruvate for three days. Flies 
were transferred to fresh vials with drug free media for recovery which lasted for 
nine days. At 3-day intervals flies were counted. The number of dead and alive flies 
were tallied. 
 
Kaplan-Meier Survivorship analysis  
The number of dead and live flies were recorded over a period of 12 days. This raw 
data was then analyzed with help from Statistix version 10 software which 
generated Kaplan- Meier survivorship plots. The Kaplan-Meier survival plot is a 
non-parametric procedure used to measure the probability of an organism to survive 
in a given time frame whilst considering time in short intervals (Goel et al., 2010). 
It is often used in medical research to ascertain the number of subjects who survived 
after an intervention. The Kaplan Meier has some complications that go with it such 
as loss or death of subjects who fail to get to the end of the experiment, these are 
called “censored observations”. The advantage of the Kaplan Meier plot includes 
the fact that it can estimate a survival curve with censored observations included. 
Along the x-axis of the Kaplan-Meier plot are horizontal lines that represent the 
duration of survival at that particular interval. This interval is aborted by the 
occurrence of an event of interest, which in our case is death. The Y-axis however 
shows the overall survival which is the percentage of subjects who haven’t 
experienced the event to that point in time on the X-axis. The formula for 
calculating the probability of survival at a given time is; 
 
St =  Number of subjects living at the start – Number of subjects dead  
Number of subjects living at the start  
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CHAPTER 3: RESULTS 
3.1 Overview of results 
The aim of this study was to determine the biochemical roles of the Retinoblastoma 
binding protein 6 (RBBP6) isoforms in metabolic reprogramming associated with 
carcinogenesis. To accomplish this, a short bioinformatics study was first 
conducted to compare RBBP6 isoforms in vertebrate and invertebrate species. 
Domains of these were analysed. Furthermore, both wild type and p53 null mutant 
Drosophila melanogaster were treated with a combination of irinotecan (a DNA 
damaging agent) and exogenous pyruvate (bypasses glycolysis) to model 
chemotherapy combined with perturbation of metabolism. The flies were treated 
for 3 days and then transferred to drug-free media to allow recovery. The day of 
transfer is regarded as day 0. Moreover, survival analysis was carried out to 
investigate how exogenous pyruvate can be used to alleviate the side effects of 
DNA damage during chemotherapy. 
Results obtained show that  the Domain with No Name (DWNN) is conserved 
through all eukaryotic organisms but not in prokaryotes. In Drosophila, SNAMA 
A and B isoforms share the first four domains. RT-PCR show that at the mRNA 
level transcripts of Snama  are expressed differentially in wild type and p53 null 
mutants following treatment with irinotecan, exogenous pyruvate and combination 
of both. Overexpression of Snama A is often accompanied by the downregulation 
of Snama B in both strains. Expression patterns of SNAMA at the protein level also 
show contrasting expression patterns (when SNAMA A is overexpressed SNAMA 
B is downregulated and vice versa) across all treatments and strains. SNAMA B 
show reduced expression when wild type flies are treated with exogenous pyruvate, 
whereas it is increased in p53 null mutants mainly when methyl pyruvate is 
combined with irinotecan. This indicates that the expression of Snama is 
independent of p53, also in some cases p53 is not involved in the transcription of 
Snama gene. Furthermore, this could also suggest that the splicing of isoforms is 
controlled. Survival analysis show that wild type flies survive more when treated 
with methyl pyruvate than with irinotecan treatment whereas p53 null mutants show 
decreased survival. This indicates that methyl pyruvate protects wild type flies from 
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irinotecan toxicity while being toxic to p53 null mutants. This is because irinotecan 
activates p53 and these flies lack p53, so they resist it while exogenous pyruvate 
enters the TCA and stimulates OXPHOS, further reversing the metabolic effect of 
these flies. 
 
3.2 Comparison of invertebrate RBBP6 isoforms to vertebrates 
using sequence alignment tools  
A short and precise bioinformatics study comparing RBBP6 isoforms in vertebrates 
(Homo sapiens RBBP6, Mice P2P-R) and invertebrates (Caenorhabditis elegans 
RBPL-1) to Drosophila melanogaster (SNAMA) was carried out. Sequences were 
obtained from the National Centre of Bioinformatics Information (NCBI) and were 
aligned using Clustal Omega (see appendix D). The results obtained show the 
different isoforms in the various organisms. Furthermore, the Domain With no 
Name is conserved through all species (Figure 3.1). SNAMA isoforms are observed 
to share the first four domains in common. The long isoform (SNAMA A) comprise 
the Rb and p53 binding domains which are essential in the cell cycle and have 
implications in carcinogenesis. 
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Figure 3.1: RBBP6 isoforms and domains of different vertebrate and invertebrate  
species. All orthologues have a common DWNN domain and most species have two 
isoforms (usually a long and short isoform) except for humans which have three. The arrow 
points at common SNAMA isoforms sharing first four domains. Sequences used to obtain 
domains were aligned using Clustal Omega.  This figure was generated using Microsoft® 
PowerPoint. 
 
 
 
DWNN
Zn CHCC
Zn RING
Proline
Coiled coil Rb Binding
P53 BindingRS Domain
Lysine Rich
Nuclear Localisation
C. Elegans RBPL-1
Isoform 1
Isoform 2
4-76 160-176 259-300 337- 349 652-667 679-773 964-1120 1433-1440
Mice P2P-R
Isoform 1
Isoform 2
4-76 160-176 259-300 337- 349 657-678 679-773 964-1120 1433-1440 1727-1790
Drosophila melanogaster SNAMA
Isoform 1
Isoform 2
4-76 160-176 259-300 337- 349 652-678 679-746 964-1120 1433-1440 1727-1790
Humans RBBP6
Isoform 1
Isoform 2
4-76 160-176 259-300 337- 349 652-678 679-773 964-1120 1433-1440
Isoform 3
1727-1790
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3.3 Expression of SNAMA in wild type Drosophila melanogaster 
during treatment and recovery 
To investigate the expression of Snama following DNA damage and upon recovery, 
RT-PCR was conducted. Furthermore the impact of boosting OXPHOS by using 
exogenous pyruvate was also assessed. Previous studies have shown that exogenous 
pyruvate enters the TCA cycle thereby boosting OXPHOS (Monchusi and Ntwasa, 
2017). Total RNA was extracted from flies after treatment and during the recovery 
period. RT-PCR results indicate that the untreated wild type Drosophila expresses 
a higher amount of Snama A compared to Snama B. However, when flies are treated 
with irinotecan, Snama B is upregulated, while Snama A remained unchanged and 
all flies died (Figure 3.2 panel B). This suggests that these isoforms are 
differentially regulated by irinotecan treatment.  
Wild type flies treated with methyl pyruvate overexpressed both isoforms during 
treatment and recovery (Figure 3.2 panel B and C). Interestingly, methyl pyruvate 
tends to upregulate the pro-proliferative Snama A. The combination of exogenous 
pyruvate with irinotecan resulted in longer survival- up to day 9 (Figure 3.2) 
indicating that exogenous pyruvate may protect normal cells against irinotecan-
induced toxicity. It is also notable that methyl pyruvate was not able to reverse the 
depletion of Snama A by irinotecan. The expression of Snama B however, is 
sustained by methyl pyruvate. (Figure 3.2). Flies treated with both drug 
permutations were observed to survive till day 9 as indicated with the red borders 
in Figure 3.2. Those treated with only irinotecan or methyl pyruvate did not survive 
till day 9.  
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Figure 3.2: Differential gene expression of Snama A and B observed during treatment 
of wild type Drosophila melanogaster. (A) RT-PCR products run on an ethidium bromide 
stained agarose gel. (B and C)   Bar charts were created by using GraphPad Prism 7 and 
results were normalised using RP49.  UNT indicates the untreated sample and 0 the last 
day of treatment. Irinotecan, methyl pyruvate and combination of both were used to treat 
flies for three days and allowed nine days for recovery. During combination treatment flies 
live till day 9 (indicated by red borders).  
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3.4 Expression of Snama in p53 null mutants during treatment and 
recovery 
Having seen the gene expression profiles of wild type Snama transcripts, we next 
investigated the expression patterns in p53 null mutants for comparative purposes. 
In this study the p53 null mutant Drosophila melanogaster were used to model 
cancer cells because of their mutated p53. Total RNA was extracted and thereafter 
RT-PCR was performed.  
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Figure 3.3: Differential gene expression of Snama A and B observed during treatment 
and recovery of p53 null mutant flies. (A) RT-PCR products run on an ethidium bromide 
stained agarose gel. (B and C)  Bar charts were created by using GraphPad Prism 7 and 
results were normalised using RP49. UNT indicates the untreated sample and 0 the last day 
of treatment. Irinotecan, methyl pyruvate and combination of both were used to treat flies 
for three days and allowed nine days for recovery. Exogenous pyruvate increases the 
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expression of the pro-proliferative Snama A and flies lived till day 9 while Snama B was 
downregulated (indicated by red borders). 
 
Results obtained show that Irinotecan treated flies lived longer although no 
expression of transcripts were observed at day 9 (Figure 3.3), suggesting that p53 
null mutants are resistant to irinotecan. Methyl pyruvate treatment upregulated the 
pro-proliferative Snama A as previously observed in wild type flies. Combination 
of irinotecan with exogenous pyruvate treatment upregulated the expression of 
Snama A throughout treatment and recovery and flies lived till day 9 (Figure 3.3). 
 
3.5 Expression of SNAMA protein in wild type Drosophila 
melanogaster during treatment and recovery 
Although RT-PCR showed the varying expression of both transcripts, protein 
production levels were investigated to compare with mRNA expression as they 
sometimes do not correlate. Proteins are known to be more stable thus it was 
important to investigate the protein expression pattern of SNAMA in p53 null 
mutants further elucidating the biochemical roles of RBBP6 isoforms in metabolic 
reprogramming which takes place following DNA damage.  Wild type flies were 
treated with irinotecan, methyl pyruvate and the combination of both. Protein was 
extracted at determined days (three-day interval from 0-9) and Western blotting 
performed. Three independent experiments were carried out and they show that 
wild type Drosophila melanogaster displayed contrasting expression patterns of 
SNAMA isoforms following treatment with irinotecan, methyl pyruvate and the 
combination of both.  
Irinotecan treated flies tend to downregulate both isoforms although SNAMA B is 
more downregulated while SNAMA A is at higher levels during recovery (Figure 
3.4). Combination treatment with exogenous pyruvate maintains this balance. 
Treatment with exogenous pyruvate causes downregulation of both isoforms in 
recovery. This downregulation was accompanied by increased survival of wildtype 
flies compared to other treatments (Figure 3.4, Figure 3.7) indicating the positive 
role methyl pyruvate might play in protecting and enhancing survival in normal 
cells.  
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Figure 3.4: Differential protein expression of SNAMA A and B observed during 
treatment and recovery of wild type flies. (A) Blots showing protein expression of 
SNAMA isoforms.  (B and C) Densitometry analysis were created by using GraphPad 
Prism 7 and results were normalised using β tubulin as the reference protein.  UNT indicates 
the untreated sample and 0 the last day of treatment. The error bars respresent the standard 
deviation between samples. Irinotecan, methyl pyruvate and combination of both were used 
to treat flies for three days and allowed nine days for recovery. Methyl pyruvate 
underexpresses SNAMA B which correlate with survival (Indicated by red border).  
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3.6 Expression of SNAMA protein in p53 null mutants Drosophila 
melanogaster during treatment and recovery 
Protein expression in p53 null mutants was investigated and compared with wild 
type flies. Flies were treated with irinotecan, methyl pyruvate and the combination 
of both. Protein was extracted, and Western blot was performed. Two independent 
experiments were carried out, and they show that when p53 null mutant flies are 
untreated SNAMA B is overexpressed and treatment with irinotecan results in a 
downregulation throughout recovery (Figure 3.5). 
Irinotecan suppressed the expression of both isoforms in p53 null mutants while 
SNAMA B dominated. Contrary to SNAMA B, p53 null mutant flies shows a 
downregulation of SNAMA A when untreated and during treatment while an 
upregulation during recovery (Figure 3.5). It appears that isoforms show contrasting 
expression patterns. Methyl pyruvate treatment shows that SNAMA A hardly varies 
staying at low levels while SNAMA B tends to increase. SNAMA B is 
overexpressed especially in combination treatment 
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Figure 3.5: Differential protein expression of SNAMA A and B observed during 
treatment and recovery of p53 null mutant flies. (A) Blots showing protein expression 
of SNAMA isoforms.  (B and C) Bar charts were created by using GraphPad Prism 7 and 
results were normalised using β tubulin as the reference protein. UNT indicates the 
untreated sample and 0 the last day of treatment. The error bars respresent the standard 
deviation between samples. Irinotecan, methyl pyruvate and combination of both were used 
to treat flies for three days and allowed nine days for recovery. Isoforms show contrasting 
expression patterns.  
 
3.7 Comparison of Snama A and B in both wild type and p53 null 
mutants during treatment and recovery 
mRNA expression levels are often used to speculate functional differences that 
occur at the protein level although they don’t always correlate to protein levels due 
to the occurrence of post-transcriptional regulation (Greenbaum et al., 2003).  
Expression patterns of both Snama isoforms in normal and p53 null mutant flies 
were compared to gain better insight into their roles in DNA-damage response. Flies 
were treated with irinotecan and exogenous pyruvate followed by Reverse 
Transcriptase Polymerase Chain Reaction as well as Western blot (Figure 3.6, Table 
3.1). 
The results obtained shows that wild type flies have contrasting expression pattern 
to p53 null mutants when treated with irinotecan alone or in combination with 
exogenous pyruvate. Exogenous pyruvate tends to upregulate Snama A. When 
Snama A is overexpressed, Snama B is downregulated at various treatments in both 
wild type and p53 null mutants (Figure 3.6 i-iii). This indicates that transcription of 
Snama is not completely dependent on p53 and the splicing of transcripts may be 
differentially controlled. At the protein level, reversed differential expression 
patterns across all treatments and strains were observed. Also, treatment with 
methyl pyruvate reduced the expression of SNAMA B in wild type flies which 
correlates with survival (Figure 3.6 v). In p53 null mutants however, SNAMA B 
was overexpressed especially in cotreatment (Figure 3.6 vi). 
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Figure 3.6: Gene (A) and protein (B) expression of Snama isoforms from wild type 
and p53 null mutant Drosophila melanogaster during treatment and recovery. Graph 
i-iii represent gene expression of Snama A and B in irinotecan (i), methyl pyruvate (ii) and 
the combination treatment (iii). Graph d-f on the other hand represent protein expression 
of isoforms in irinotecan (iv) methyl pyruvate (v) and combination treatment (vi). 
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Table 3.1: Regulation of SNAMA isoforms during treatment and recovery. 
 
T- Treatment 
R- Recovery 
D- Dead before day 9 
S- Survived till day 9 
Up- Up regulated 
Down- Down regulated 
 
3.8 Survival Analysis of wild type and p53 null mutants  
The survival trends of wild type and p53 null mutants were studied to investigate 
the effects of exogenous pyruvate during DNA damage. Flies were treated with 
irinotecan, methyl pyruvate and the combination of both for three days and allowed 
nine days recovery period and counted in three-day intervals. Results obtained show 
that the untreated wild type had a better survival trend than all three treatments as 
expected. Furthermore, exposure to exogenous pyruvate increases survival in wild 
type flies compared to irinotecan treated (Figure 3.7). When methyl pyruvate is 
 
mRNA expression 
Snama A  Snama B  
Wild type P53 null mutants Wild type P53 null mutants 
Irinotecan Up (T), Down (R) Up (T), Up (R) IR Up (T), Up (R) 
 
Down (T), Up (R) 
 
Methyl 
Pyruvate 
Up (T), Up (R) 
 
Up (T), Up (R) 
 
MP Up (T), Up (R) 
 
Down (T), Down (R) 
 
Co-
Treatment 
Up (T), Up (R) 
 
Up (T), Up (R) COT Up (T), Up(R) Up (T), Down (R) 
Protein expression 
SNAMA A SNAMA B 
Wild type P53 null mutants Wild type P53 null mutants 
Irinotecan Down (T), Down (R) 
D 
Down (T), Up (R) 
D 
IR Up (T), Down (R) 
D 
Down (T), Down (R) 
D 
Methyl 
Pyruvate 
Up (T), Down (R) 
S 
Up (T), Up (R) 
D 
MP Up (T), Down (R) 
S 
Down (T), Down (R) 
D 
Co-
Treatment 
Up (T), Down (R) 
D 
Up (T), Up (R) 
D 
COT Up (T), Down (R) 
D 
Down (T), Down (R) 
D 
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combined with irinotecan this also improved survival in wild type flies. This 
indicates that methyl pyruvate protects wild type flies from DNA damage.  
 
 
 
Figure 3.7: Survival analysis of wild type Drosophila melanogaster. Untreated flies 
showed better survival than all treatments as expected. Methyl pyruvate increases survival 
of flies compared to irinotecan. Figure was generated using Statistix 10 software. 
 
In p53 null mutants, combination treatment with methyl exogenous pyruvate and 
irinotecan results in less survival during early recovery days (kills p53 null mutants) 
compared to irinotecan alone (Figure 3.8). This indicates that exogenous pyruvate 
induces toxicity in p53 null mutants.  
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Figure 3.8 Survival analysis of p53 null mutant Drosophila melanogaster. P53 null 
mutants have a better survival trend when treated with irinotecan compared to methyl 
pyruvate which results in less  survival. Figure was generated using Statistix 10 software. 
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CHAPTER 4: DISCUSSION 
4.1 Overview 
Retinoblastoma binding protein 6 is an important protein in embryonic 
development and in carcinogenesis. This study investigated the roles of SNAMA 
(the Drosophila orthologue) isoforms in metabolic reprogramming occurring during 
carcinogenesis. Wild type and p53 null mutant Drosophila melanogaster were used 
as a model for normal and cancer cells respectively. Comparison of RBBP6 
isoforms in vertebrate and invertebrates was done using sequence alignment tools. 
Survival analysis was carried out using Kaplan Meier plot to investigate the role of 
exogenous pyruvate in protecting normal cells during irinotecan induced DNA 
damage. Evidence suggest that p53 mutation can induce the Warburg effect, this 
study observed this can be reversed by exogenous pyruvate. Moreover, expression 
patterns of the isoforms were investigated using Reverse Transcriptase Polymerase 
Chain Reaction and Western blot analysis. 
We found that the two Drosophila melanogaster isoforms, SNAMA A and B are 
expressed contrastingly depending on the stress they encounter and may play roles 
in carcinogenesis. They may probably be involved in the apoptotic pathway where 
they either stimulate or repress it. SNAMA B probably antagonizes SNAMA A 
leading to its reduced expression. Similarly, just like in humans (specifically in 
polyadenylation) where the smaller isoform 3 which is structurally similar to 
SNAMA B antagonizes the larger isoform by competitive binding. SNAMA B may 
also function like the human isoform 3 whereas SNAMA A may function like 
Mdm2. This suggestion is made following the observation that they share similar 
structural domains and function in inhibiting p53. Furthermore, we also observed 
that bypassing the glycolytic pathway by treatment with methyl pyruvate affects the 
expression of SNAMA isoforms leading to divergent effects on normal and p53 
null mutants. This change in expression brought about by methyl pyruvate 
correlated with increased survival in normal flies undergoing chemotherapy and 
decreased survival in p53 null mutant flies indicating that methyl pyruvate might 
probably induce apoptosis in a p53 independent manner. 
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4.2 SNAMA isoforms show contrasting expression patterns 
following irinotecan induced DNA damage  
During carcinogenesis, cancer cells prefer glycolysis circumventing OXPHOS. 
This study investigated possible roles that SNAMA isoforms (Drosophila 
orthologue of RBBP6) may play during DNA damage and metabolic 
reprogramming. This was done by observing SNAMA expression profile of 
wild type and p53 null mutants following treatment with irinotecan (to induce 
DNA damage) and exogenous pyruvate (to boost OXPHOS). Reverse 
Transcriptase Polymerase Chain Reaction and Western blot analysis were 
carried out. It was observed that both isoforms show contrasting expression 
patterns in wild type and p53 null mutants across all treatments. SNAMA A is 
increased in untreated wild type and reduced in untreated p53 null mutant flies. 
On the other hand, SNAMA B is reduced in untreated wild type and increased 
in untreated p53 null mutants, showing differential expression. Interestingly, in 
untreated p53 null mutants SNAMA A is decreased whilst SNAMA B is 
increased. This suggests that both isoforms may probably play roles that vary 
in the presence or absence of p53. SNAMA B showed reduced expression when 
wild type files were treated with methyl pyruvate, whereas it was increased in 
p53 null mutants mainly when methyl pyruvate was combined with irinotecan. 
This suggests that the absence of p53 increases the pro-apoptotic SNAMA A, 
indicating that the expression of SNAMA is not completely dependent on p53. 
Thus, SNAMA B is the probable pro-apoptotic isoform and SNAMA A anti- 
apoptotic. 
SNAMA shows some striking similarities with MDM2. P53 activates the 
transcription of MDM2 and upon expression MDM2 negatively regulates p53. 
Work done by Hull and colleagues (2015) showed that Snama has a p53 binding 
domain suggesting it can possibly transcriptionally activate Snama. 
Nonetheless, there are situations where p53 can be upregulated without Snama 
transcripts being upregulated. Also, situations where p53 is absent and Snama 
transcripts fluctuates. This indicates that there are some cases where p53 is not 
involved in the transcription of Snama gene. Since Snama A and B are spliced 
products, it is also possible their splicing is also controlled. 
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SNAMA A and B probably have different roles and their function may 
counteract one another. In this study, we observed that during the 
overexpression of Snama A, Snama B is underexpressed and vice versa 
especially in p53 null mutant flies further suggesting they may possibly be 
involved in divergent roles. This is not surprising as it has been observed that 
the different isoforms of the human RBBP6 play different roles. For example, 
the human isoform 3 of RBBP6, which comprises only the DWNN domain 
plays a role in regulating the cell cycle at G2/M and its down regulation reduces 
apoptosis, while the under expression of isoform 1 leads to reduced cell 
proliferation. These roles counteract one another (Mbita et al., 2012; Ntwasa, 
2016). The possibly different roles that may be played by SNAMA isoforms 
might be due to the fact that although they share similar binding domains, they 
also differ in some. However, their similarities in domain structures might also 
lead to competitiveness for binding sites. Due to their differences in domain 
structure, for example the nuclear localisation domain only present in SNAMA 
A, they may function in different locations within the cell. SNAMA A may 
probably function in the nucleus while SNAMA B in the cytoplasm. 
This study suggests that SNAMA B might have an antagonistic role towards 
SNAMA A.  In humans, the short isoform structurally similar to SNAMA B 
antagonises the larger isoform by competitive binding to the cleavage 
stimulation factor (CstF) complex that is involved in the 3' end cleavage and 
polyadenylation of pre-mRNAs (Di Giammartino et al., 2014). In Drosophila 
melanogaster, a similar trend was observed where SNAMA B confidentially 
appears to under- express SNAMA A. A hypothetic model of how SNAMA 
isoforms antagonizes one another and how they may probably be involved in 
apoptosis is shown in the diagram below (Figure 4.1). It illustrates how the 
inhibition of SNAMA A by SNAMA B represses Dmp53 activation which leads 
to reduced apoptosis. However, in p53 null mutants it is suspected that addition 
of exogenous pyruvate might induce apoptosis independently of p53 following 
the intrinsic (death) pathway. 
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Further elucidation of the roles of SNAMA isoforms especially in regard to 
apoptosis is crucial as it might help in the discovery of novel treatment 
strategies. 
 
Figure 4.1: Hypothetic model of how SNAMA isoforms may produce the antagonistic 
roles. This schematic diagram shows the apoptotic pathway where irinotecan induces DNA 
damage which then stimulates Mei-41, then Dmp53 induction either activates the cell cycle 
arrest pathway or apoptosis. In wild type SNAMA B inhibit SNAMA A which then inhibits 
Dmp53 leading to reduced apoptosis. In p53 null mutants, cell death may occur 
independently of p53 with help from methyl pyruvate. 
 
4.3 SNAMA may be a functional homolog of Mdm2 
Several studies have observed the roles of MDM2 in cancers. Of note is its 
overexpression in several tumours, in fact it is suggested to be a potential biomarker 
in this regard. This overexpression has also been linked to poor prognosis, 
metastasis and drug resistance. However, during cancer treatment, the expression 
of MDM2 decreases and when it is knocked down cancer cells die (Jones et al., 
1995; Shi and Gu, 2012). This study has used p53 null mutant flies as models of 
cancers as p53 is mutated and non-functional in over 50% of cancers. Using Reverse 
Transcriptase Polymerase Chain Reaction and Western blot analysis, the 
biochemical roles of SNAMA isoforms were investigated. Flies were treated with 
irinotecan, methyl pyruvate and the combination of both and left to recover. 
Results showed molecular changes in treated and recovering flies. Chemotherapy 
(irinotecan treatment) and treatment with methyl pyruvate were observed to reverse 
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expression of both SNAMA isoforms compared to untreated wild type and p53 null 
mutant flies. This reversal of expression correlates to poor survival in p53 null 
mutant flies indicating p53 independent apoptosis. The similarity of expression 
patterns of SNAMA and MDM2 in normal and cancerous cells is striking 
suggesting SNAMA may in fact act as a functional homolog of MDM2. It is 
interesting to note that there is currently no identified homolog of MDM2 in 
Drosophila melanogaster. 
Both RBBP6 and MDM2 proteins are nuclear proteins that comprise the E3 ligase 
activity and catalyse ubiquitination substrates such as p53 (Chibi et al., 2008). It 
has been observed that in mammals MDM2 and RBBP6 are structurally similar, 
possessing domains such as the RING finger, p53 binding and pRb binding sites. 
Both proteins are important during embryogenesis, deletion or knockdown of 
SNAMA leads to death of embryos (Hull et al., 2015). The same with absence of 
PACT (RBBP6 homolog in mice) results in early death and they die with a posterior 
phenotype. This phenotype is rescued when both p53 and PACT are knocked down 
(Jones et al., 1995). Similarly, it was observed when both SNAMA and p53 were 
absent flies lived (Nweke, 2015) indicating the absence of apoptosis. 
This study proposes that SNAMA likely functions similarly to MDM2 due to the 
identification of some structural and functional similarities. For example, both 
SNAMA and MDM2 are negative regulators of p53 and are both important in 
development. However, the mechanism of action of SNAMA is still not fully 
understood. 
The possible role of SNAMA as a functional homolog of MDM2 further 
strengthens its proposal as a good target for cancer treatment. 
 
4.4 Exogenous pyruvate protects wild type flies from irinotecan 
toxicity while killing p53 null mutants 
The commitment of cancer cells to the Warburg effect is a hallmark of cancer. 
Reversing this metabolic shift can help in killing cancer cells while saving normal 
cells. The effects of circumventing the glycolytic pathway was investigated in this 
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study. Wild type and p53 null mutant Drosophila melanogaster were treated with 
irinotecan and methyl pyruvate. Irinotecan was used to induce DNA damage while 
exogenous pyruvate used to perturb metabolism and bypass the glycolytic pathway. 
Results showed that when wild type and p53 null mutants were treated with 
irinotecan did not live past day six of recovery suggesting an unbiased toxicity to 
normal and cancer cells. Irinotecan targets rapidly dividing cells. Rapid division of 
cells can also be observed in normal cells especially during DNA replication. For 
example, cells in the hair, blood, epithelial, bone marrow, get targeted due to their 
fast replicating nature. During chemotherapy, p53 gets activated by irinotecan 
(Takeba et al., 2007), consequently inducing apoptosis. The toxicity of irinotecan 
to normal cells have been identified in several studies (Xu, 2002) and is noted to be 
one of the cons of chemotherapy. 
In this study, it was further observed that the introduction of exogenous pyruvate, 
increased survival in wild type flies compared to irinotecan treatment which killed 
them. On the other hand, p53 null mutants were less susceptible to irinotecan than 
wildtype. Since irinotecan activates p53 and null mutants lack p53, they become 
resistant to it and survive longer, however, exogenous pyruvate remarkably kills 
them. Since p53 is involved in the regulation of the glycolytic pathway, bypassing 
it might decrease p53 dependent apoptosis and thus increase survival. On the other 
hand, p53 null mutant flies didn’t survive when treated with methyl pyruvate 
suggesting methyl pyruvate induces p53 independent apoptosis. Cancer cells prefer 
to metabolise glucose using the inefficient glycolysis pathway even in an abundant 
presence of oxygen. This is called the Warburg effect. In contrast, normal cells 
prefer mitochondrial OXPHOS which yields a net total of 36 ATP molecules 
compared to only two in glycolysis. This study exposed flies to exogenous 
pyruvate, thus providing the end product of glycolysis and consequently bypassing 
the pathway. 
In cancer cells and models, exogenous pyruvate treatment reverses the metabolic 
reprogramming and is thus toxic to them and enhances the expression of isoforms. 
The observations of the effect of exogenous pyruvate correlates with work done by 
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Monchusi and Ntwasa (2017) in which exogenous pyruvate protected the normal 
lung fibroblast MRC-5 cells from irinotecan toxicity but killed cancer cells. 
 
4.5 Conclusion 
This study has shed light on the possible roles of RBBP6 isoforms during metabolic 
reprogramming and carcinogenesis. Further evidence that Drosophila 
melanogaster homologue of RBBP6- SNAMA- may be a functional homologue of 
MDM2 is provided and thus a negative regulator of p53. Furthermore, SNAMA 
isoforms display contrasting expression patterns depending on the stress brought 
upon them. The expression of these isoforms is further affected during the 
circumvention of metabolic reprogramming. Moreover, bypassing the glycolytic 
pathway by the use of exogenous pyruvate has diverse effects in normal cells (wild 
type flies) and a cancer model (p53 null mutant flies), having protecting effects on 
the former and killing the latter. These observations hint at the crucial role of 
RBBP6 in carcinogenesis and as a potential druggable target for cancer therapy. 
Future studies validating the roles of RBBP6 investigating the use of RBBP6 as a 
target in cancer therapy may help in the discovery of novel treatment and 
management regimens.  
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APPENDIX  
Appendix A: Lab equipment 
 
Table A1: Laboratory equipment, manufactures and model number of equipment 
used in this study. 
 LAB EQUIPMENT  
 
MANUFACTURER & MODEL NO. 
Biofuge pico (centrifuge machine) Heraeus Instruments  
D-31520 
Computer Controlled Electrophoresis 
power supply 
 Bio-Rad  
3000Xi 
Digital dry bath Labnet   
D1100-230v 
GeneAmp PCR System 
 
Perkin Elmer  
2400 
Gel doc System 
 
Bio-Rad   
XR+ 
INJECT+ MATIC sleeper® 
 
Geneve  
CG-1207 
Laboratory labelling system 
 
LAB XPERT™   
XC-500-461 
Magnetic stirrer   Freed Electric  
MH4-9517 
Microwave Oven 
 
KIC  
MWS- 900M 
Motor Heidolph  
50300 
Water bath Julabo p   
130 
Weighing balance 
 
Precisa   
XT220A 
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G10 Gyrotory® Shaker New Brunswick Scientific (U.S.A) 
3,430,926 
Junior Orbit Shaker LAB-LINE 
3521 3522-1 
Nanodrop® spectrophotometer Thermo Fischer Scientific USA  
1000 
Hoefer VE blotting module Amersham Biosience UK 
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Appendix B: Buffers 
 
Table A2: Buffers and their compositions used in this study. 
BUFFERS COMPOSITION 
2X SDS Sample buffer 
 
 
1 M Tris-HCl buffer (pH 6.8) 
50% Glycerol, 10% SDS 
0.5% β-Mercaptoethanol 
4.4 % Bromophenol blue 
1X PBST 
 
 
0.05 M Phosphate Buffers 
Tween-20 
5.67 M NaCl 
0.01 M KCl 
5X Running buffer 25 mM Tris 
192 mM glycine 
1% SDS 
Tris-HCL pH 6.8 0.5 M TRIS (hydroxymethyl) aminomethane 
Tris-HCL pH 8.8 1.5M TRIS (hydroxymethyl) aminomethane 
10% Ammonium persulphate 100mg Ammonium Persulphate + 1ml dH20 
10% SDS 10% SDS 
TOWBIN / Transfer buffer 
(pH8.3) 
25 mM Tris base 
192 mM glycine 
0.1%SDS  
20% (v/v) methanol on day of use. 
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Appendix C: Chemicals 
 
Table A3: Chemicals, catalogue numbers as well as suppliers used in this study. 
CHEMICALS CATALOGUE 
NO. 
SUPPLIER 
2- Mercapto Ethanol M-3148 
 
SIGMA 
Acrylamide A3699 SIGMA 
Acetic acid glacial 2789 MERCK 
Agar Agar Powder 1037407 MERCK 
Agarose Powder 50004 WhiteSci 
Ammonium persulphate A0118ǀO00500 ASSOCIATED 
CHEMICAL 
ENTERPRISES 
Bio-rad protein assay 500-0006 BIO-RAD 
Ethanol absolute 20821.330 VWR CHEMICALS 
Glycerol 2676500LC MERCK 
Glycine G8898 SIGMA 
Irinotecan hydrochloride L1406-   SIGMA  
 
Methanol 781114 RAD-CHEM  
Methyl 4- hydroxybenzoate H5501 SIGMA 
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Methyl pyruvate 
 
371173 SIGMA 
Nuclease free water 
 
129117 QIAGEN 
Phosphate Buffered Saline P4417 SIGMA 
PCR Mastermix 2X 
 
M0482S NEW ENGLAND 
BIOLABS 
Streptomycin sulfate salt A9518 SIGMA 
Propan-2-ol 5075040LC VWR CHEMICALS 
Sodium Dodecyl Sulphate 442444H VWR CHEMICALS 
Super block PBS blocking 37580 THERMO SCIENTIFIC 
TEMED T 8133 SIGMA 
Tris (hydroxymethyl) 
amiomethane 
T 1503 SIGMA 
TWEEN 20 
 
DB0560 
 
BIO BASIC INC. 
TRI Reagent T9424 SIGMA 
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Appendix D: Aligned Sequences of RBBP6 isoforms from different 
organisms  
 
KEY: 
Human (RBBP6)  
A1 Isoform 1    (NP_008841.2)    
A2 Isoform 2    (NP_061173.1) 
A3 Isoform 3    (NP_1160152)  
Mice ( P2P-R)  
A4 Isoform 1    (NP_035377.2) 
A5 Isoform 2    (NP_778188.1) 
Drosophila (SNAMA)  
A6 Isoform A    (NP_611884.1) 
A7 Isoform B    (NP_001246487.1) 
C. elegans (RBPL-1)  
A8 Isoform 1    (NP_001032975.1) 
A9 Isoform 2    (AJ34990.1)     
CLUSTAL O(1.2.4) multiple sequence alignment 
 
 
A8      MSSIHYKFRAELDYKTLQFDGLHIRGEQLVREICAKENL-KLELFELQLQNAHTKKTYSD 
A9      MSSIHYKFRAELDYKTLQFDGLHIRGEQLVREICAKENL-KLELFELQLQNAHTKKTYSD 
A6      -MSVHYKFKSTLNFDTITFDGLHISVGDLKREIVQQKRLGKIIDFDLQITNAQSKEEYKD 
A7      -MSVHYKFKSTLNFDTITFDGLHISVGDLKREIVQQKRLGKIIDFDLQITNAQSKEEYKD 
A3      MSCVHYKFSSKLNYDTVTFDGLHISLCDLKKQIMGREKL-KAADCDLQITNAQTKEEYTD 
A5      MSCVHYKFSSKLNYDTVTFDGLHISLCDLKKQIMGREKL-KAADSDLQITNAQTKEEYTD 
A4      MSCVHYKFSSKLNYDTVTFDGLHISLCDLKKQIMGREKL-KAADSDLQITNAQTKEEYTD 
A1      MSCVHYKFSSKLNYDTVTFDGLHISLCDLKKQIMGREKL-KAADCDLQITNAQTKEEYTD 
A2      MSCVHYKFSSKLNYDTVTFDGLHISLCDLKKQIMGREKL-KAADCDLQITNAQTKEEYTD 
          .:**** : *::.*: ******   :* ::*  ::.* *    :**: **::*: *.* 
 
A8      D-ELIPRNSSIIVQRFPRKDAAKVQKVQAGVNSGMVNQLDATS--------SFLDPSSHI 
A9      D-ELIPRNSSIIVQRFPRKDAAKVQKVQAGVNSGMVNQLDATS--------SFLDPSSHI 
A6      DGFLIPKNTTLIISRIPIAHPTKK--GWEP--PAAENAFSAA----------PAKQDNFN 
A7      DGFLIPKNTTLIISRIPIAHPTKK--GWEP--PAAENAFSAA----------PAKQDNFN 
A3      DNALIPKNSSVIVRRIPIGGVKSTSKTYVI--SRTEPAMATTKAVCKNTISHFFYTLLLP 
A5      DNALIPKNSSVIVRRIPIGGVKSTSKTYVI--SRTEPVMGTTKAVCKNTITLFLHNCFYL 
A4      DNALIPKNSSVIVRRIPIGGVKSTSKTYVI--SRTEPVMGTTKAIDDASASISLAQLTKT 
A1      DNALIPKNSSVIVRRIPIGGVKSTSKTYVI--SRTEPAMATTKAIDDSSASISLAQLTKT 
A2      DNALIPKNSSVIVRRIPIGGVKSTSKTYVI--SRTEPAMATTKAIDDSSASISLAQLTKT 
        *  ***:*:::*: *:*     .               : ::                   
 
A8      SSAEFENMDEAERLNHIRDQSTRAYDQSNFRRRQPGIMTGPPPPTYTCNRCSQPGHWYKN 
A9      SSAEFENMDEAERLNHIRDQSTRAYDQSNFRRRQPGIMTGPPPPTYTCNRCSQPGHWYKN 
A6      MDLSKMQGTEEDKIQAMMMQSTVDYDPKTYHRIKGQSQVGEVPASYRCNKCKKSGHWIKN 
A7      MDLSKMQGTEEDKIQAMMMQSTVDYDPKTYHRIKGQSQVGEVPASYRCNKCKKSGHWIKN 
A3      L----------------------------------------------------------- 
A5      YNVSVT------------------------------------------------------ 
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A4      ANLAEANASEEDKIKAMMSQSGHEYDPINYMK---KTLVGPPPPSYTCFRCGKPGHYIKN 
A1      ANLAEANASEEDKIKAMMSQSGHEYDPINYMK---KP-LGPPPPSYTCFRCGKPGHYIKN 
A2      ANLAEANASEEDKIKAMMSQSGHEYDPINYMK---KP-LGPPPPSYTCFRCGKPGHYIKN 
                                                                     
 
A8      CPMLNT---------KRTTGIPSQELMETTV-DDPDAMMHPSGKYVIPIMHWKARQETLA 
A9      CPMKLQ---------APKTKVKREDKKRDDR----------------------------- 
A6      CPFVGGKDQQ---EVKRNTGIPRSFRDKPDAAEN------ESADFVLP------------ 
A7      CPFVGGKDQQ---EVKRNTGIPRSFRDKPDAAEN------ESADFVLP------------ 
A3      ------------------------------------------------------------ 
A5      ------------------------------------------------------------ 
A4      CPTNGDKNFESGPRIKKSTGIPRSFMMEVKDPNMKGAMLTNTGKYAIPTIDAEAYAIGKK 
A1      CPTNGDKNFESGPRIKKSTGIPRSFMMEVKDPNMKGAMLTNTGKYAIPTIDAEAYAIGKK 
A2      CPTNGDKNFESGPRIKKSTGIPRSFMMEVKDPNMKGAMLTNTGKYAIPTIDAEAYAIGKK 
                                                                     
 
A8      RK---NEDGSSSPAQTSRKVPPELLCPICQSLFKEAIVTSCCGNSYCADCIEARILDPDN 
A9      ------------------------------------------------------------ 
A6      -------------AVQNQEIPEDLICGICRDIFVDAVMIPCCGSSFCDDCVRTSLLESED 
A7      -------------AVQNQEIPEDLICGICRDIFVDAVMIPCCGSSFCDDCVRTSLLESED 
A3      ------------------------------------------------------------ 
A5      ------------------------------------------------------------ 
A4      EKPPFLPEEPSSSSEEDDPIPDELLCLICKDIMTDAVVIPCCGNSYCDECIRTALLESDE 
A1      EKPPFLPEEPSSSSEEDDPIPDELLCLICKDIMTDAVVIPCCGNSYCDECIRTALLESDE 
A2      EKPPFLPEEPSSSSEEDDPIPDELLCLICKDIMTDAVVIPCCGNSYCDECIRTALLESDE 
                                                                     
 
A8      QKCPGADCGKDISITSIIPNKTLRDAAAAWLSATGPGAPTTPQIVPEPEQ------IRIR 
A9      ------------------------------------------------------------ 
A6      SECPDCK-EKNCSPGSLIPNRFLRNSVNAFKNETGYNKSAAKPAAVKNEEKPPVEKEVEK 
A7      SECPDCK-EKNCSPGSLIPNRFLRNSVNAFKNETGYNKSAAKPAAVKNEEKPPVEKEVEK 
A3      ------------------------------------------------------------ 
A5      ------------------------------------------------------------ 
A4      HTCPTCH-QNDVSPDALIANKFLRQAVNNFKNETGYTKRLRKQLPPPPPPVPPPRPLMQR 
A1      HTCPTCH-QNDVSPDALIANKFLRQAVNNFKNETGYTKRLRKQLPPPPPPIPPPRPLIQR 
A2      HTCPTCH-QNDVSPDALIANKFLRQAVNNFKNETGYTKRLRKQLPPPPPPIPPPRPLIQR 
                                                                     
 
A8      ---IGLK---------------------APSSSQSQITPSGISPGST--------LVQQQ 
A9      ------------------------------------------------------------ 
A6      -------KPVAEV-EPEETEV-------KPEKQ-KESETNGSNPPKS------ESPEPPA 
A7      -------KPVAEV-EPEETEV-------KPEKQ-KESETNGSNPPKS------ESPEPPA 
A3      ------------------------------------------------------------ 
A5      ------------------------------------------------------------ 
A4      NLQPLMRSPISRQQDPLMIPVTSSSAHSAPSISSLTSNPSALAPSVSGNPSSAPAPVPDI 
A1      NLQPLMRSPISRQQDPLMIPVTSSSTHPAPSISSLTSNQSSLAPPVSGNPSSAPAPVPDI 
A2      NLQPLMRSPISRQQDPLMIPVTSSSTHPAPSISSLTSNQSSLAPPVSGNPSSAPAPVPDI 
                                                                     
 
A8      T---------------------------TLTSV-SSGTSL-------------------- 
A9      ------------------------------------------------------------ 
A6      TTEPS-QKEKDKYDSDYEDNITIKMPQPAADS---------------------------- 
A7      TTEPS-QKEKDKYDSDYEDNITIKMPQPAADS---------------------------- 
A3      ------------------------------------------------------------ 
A5      ------------------------------------------------------------ 
A4      TATVSISVHSEKSDGPFRDSDNKLLPAAALTSEHSKGASSIAITALMEEKGYQVPVLGTP 
A1      TATVSISVHSEKSDGPFRDSDNKILPAAALASEHSKGTSSIAITALMEEKGYQVPVLGTP 
A2      TATVSISVHSEKSDGPFRDSDNKILPAAALASEHSKGTSSIAITALMEEKGYQVPVLGTP 
                                                                     
 
A8      ----------------------SAQPS--------------------------------- 
A9      ------------------------------------------------------------ 
A6      ----------------------TTVPSKRSPSYSHRSES---------SHRRDRSDYVSD 
A7      ----------------------TTVPSKRSPSYSHRSES---------SHRRDRSDYVSD 
A3      ------------------------------------------------------------ 
69 
 
A5      ------------------------------------------------------------ 
A4      SLLGQSLLHGQLIPTTGPVRINAARPGGGRPGWEHSNKLGYLVSPPQQIRRGERSCYRSI 
A1      SLLGQSLLHGQLIPTTGPVRINTARPGGGRPGWEHSNKLGYLVSPPQQIRRGERSCYRSI 
A2      SLLGQSLLHGQLIPTTGPVRINTARPGGGRPGWEHSNKLGYLVSPPQQIRRGERSCYRSI 
                                                                     
 
A8      ------------NVNPSIPGIPLASQVPSM----------------VQDVSLPPPQLRQE 
A9      ------------------------------------------------------------ 
A6      HDHKHQ--RPS--KSESVNKDRSLLPLPIGTLPSYQGHMMAESEEARRSSAYKPPY--MQ 
A7      HDHKHQ--RPS--KSESVNKDRSLLPLPIGTLPSYQGHMMAESEEARRSSAYKPPY--MQ 
A3      ------------------------------------------------------------ 
A5      ------------------------------------------------------------ 
A4      NRGRHHSERSQRTQGPSLPATPVFVPVPPP-------------------PLYPPPPHTLP 
A1      NRGRHHSERSQRTQGPSLPATPVFVPVPPP-------------------PLYPPPPHTLP 
A2      NRGRHHSERSQRTQGPSLPATPVFVPVPPP-------------------PLYPPPPHTLP 
                                                                     
 
A8      LPPGIPGLPQFGLPPPGVPGLSATVLPQHQSMPLNYGM----PLFSAGFPPAVSSVPRPS 
A9      ------------------------------------------------------------ 
A6      MQRGPPPMHMMS---HHMPAYNNGFNNMGQRPPLSYVPYQNQSVHPMRAPYGSAGGGMNM 
A7      MQRGPPPMHMMS---HHMPAYNNGFNNMGQRPPLR------------------------- 
A3      ------------------------------------------------------------ 
A5      ------------------------------------------------------------ 
A4      LPPGVPPP-----------QFSPQF-PPGQPPPAGYSV------PPPGFP------PAPA 
A1      LPPGVPPP-----------QFSPQF-PPGQPPPAGYSV------PPPGFP------PAPA 
A2      LPPGVPPP-----------QFSPQF-PPGQPPPAGYSV------PPPGFP------PAPA 
                                                                     
 
A8      AISDEWN-------------------------AFLQNKDRNSSRR---DHKDRTR----- 
A9      ------------------------------------------------------------ 
A6      NMSQPFQSPNLASIYQGVAAKVGSGPIDDPLEAFN---RIMKEKE--RKKVDRFR----- 
A7      ------------------------------------------------------------ 
A3      ------------------------------------------------------------ 
A5      ------------------------------------------------------------ 
A4      NISTPWVSSGVQTAHSNTIPTTQAPPLSR--EEFYREQRRLKEEEKKKSKLDEFTNDFAK 
A1      NLSTPWVSSGVQTAHSNTIPTTQAPPLSR--EEFYREQRRLKEEEKKKSKLDEFTNDFAK 
A2      NLSTPWVSSGVQTAHSNTIPTTQAPPLSR--EEFYREQRRLKEE---------------- 
                                                                     
 
A8      ------RKDRHDSRSRRRRDSSSSSSMSSSSS-DEDERR----RKRREK--ESSKKRRSV 
A9      ------------------------------------------------------------ 
A6      ------SSDRHRSRSPDRQRHRFKSPMY-----EKDNSRDNLKDKRP------------- 
A7      ------------------------------------------------------------ 
A3      ------------------------------------------------------------ 
A5      ------------------------------------------------------------ 
A4      ELMEYKKIQKERRRSFSRSKSPYSGSSYSRSSYTYSKSRSGSTRSRSYSRSFSRSHSRSY 
A1      ELMEYKKIQKERRRSFSRSKSPYSGSSYSRSSYTYSKSRSGSTRSRSYSRSFSRSHSRSY 
A2      ------------------SKSPYSGSSYSRSSYTYSKSRSGSTRSRSYSRSFSRSHSRSY 
                                                                     
 
A8      EK--ERPRRADEHRRDRDRDRERDRDRSHRDVRSSGRSKDIKASSSHRRDRDDARRKDRR 
A9      ------------------------------------------------------------ 
A6      --------------------RSRERKREHSYERHIRHPRSSRQPNDGS------------ 
A7      ------------------------------------------------------------ 
A3      ------------------------------------------------------------ 
A5      ------------------------------------------------------------ 
A4      SRSPPYPRRGRGK-----SRNYRSRSRSHGYHRSRSRSPPYRRYHSRSRSPQAFRGQSPT 
A1      SRSPPYPRRGRGK-----SRNYRSRSRSHGYHRSRSRSPPYRRYHSRSRSPQAFRGQSPN 
A2      SRSPPYPRRGRGK-----SRNYRSRSRSHGYHRSRSRSPPYRRYHSRSRSPQAFRGQSPN 
                                                                     
 
A8      RDDVRKKERREKREEEDDDQKTKDAESKDEDEIDIDGIIAEYGNVQA------------- 
A9      ------------------------------------------------------------ 
A6      --KSPGG--RIKRSGH-----RRSASP--KPGY-----------KSDYRD---------- 
A7      ------------------------------------------------------------ 
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A3      ------------------------------------------------------------ 
A5      ------------------------------------------------------------ 
A4      KRNVPQG--ETEREYF-----NRYREV--PPPYD---IKAYYGRSVDFRDPFEKERYREW 
A1      KRNVPQG--ETEREYF-----NRYREV--PPPYD---MKAYYGRSVDFRDPFEKERYREW 
A2      KRNVPQG--ETEREYF-----NRYREV--PPPYD---MKAYYGRSVDFRDPFEKERYREW 
                                                                     
 
A8      ---------QDTDGDAQVADENAQNDEDSTSPKEESVSPKPDETHEEDADEEPVDEEM-- 
A9      ------------------------------------------------------------ 
A6      ---------KPY---NKP-----------SAPKTEAVEPPPPGFEPLQLTDED------- 
A7      ------------------------------------------------------------ 
A3      ------------------------------------------------------------ 
A5      ------------------------------------------------------------ 
A4      ERKYREWYEKYYKGYAVG---------AQPRPSANREDFSPERLLPLNIRNSPFTRGRRE 
A1      ERKYREWYEKYYKGYAAG---------AQPRPSANRENFSPERFLPLNIRNSPFTRGRRE 
A2      ERKYREWYEKYYKGYAAG---------AQPRPSANRENFSPERFLPLNIRNSPFTRGRRE 
                                                                     
 
A8      --DTEVVVRDKSIDPVYQAMETSEAEVAETKEESVPVEEDEEPENHDEDVEDHKKEKESQ 
A9      ------------------------------------------------------------ 
A6      GYRNKH-----------PTS---------------------------------SEA--SQ 
A7      ------------------------------------------------------------ 
A3      ------------------------------------------------------------ 
A5      ------------------------------------------------------------ 
A4      DYAAGQSHRNRNLGGNYPEK---------------------------------LSTRDSH 
A1      DYVGGQSHRSRNIGSNYPEK---------------------------------LSARDGH 
A2      DYVGGQSHRSRNIGSNYPEK---------------------------------LSARDGH 
                                                                     
 
A8      SSTINTADEDDESSKKMKKHKKSKKNKKHHRKEEDGDEDEERKRKKHKKHKKEKKSKKEK 
A9      ------------------------------------------------------------ 
A6      SSK-------GDSSK----------------KRGENR----HEEAPRKRHRSRSISKEPK 
A7      ------------------------------------------------------------ 
A3      ------------------------------------------------------------ 
A5      ------------------------------------------------------------ 
A4      NAKDNPKSKEKESEN----------------VPGDGK----GN--KHKKHRKRRKGEE-- 
A1      NQKDNTKSKEKESEN----------------APGDGK----GN--KHKKHRKRRKGEE-- 
A2      NQKDNTKSKEKESEN----------------APGDGK----GN--KHKKHRKRRKGEE-- 
                                                                     
 
A8      RDE--DEDDLDTEKKEKK-------------KERKYQDDK--DEDSNRKE--------PR 
A9      ------------------------------------------------------------ 
A6      PNDSNYRSLTPPAKITTP--------------------------------KMTAAQLRQR 
A7      ------------------------------------------------------------ 
A3      ------------------------------------------------------------ 
A5      ------------------------------------------------------------ 
A4      -----SESFLNPELLETSRKCRESSGIDETKTDTLFVLPSRDDATPVRDEPMDAESITFK 
A1      -----SEGFLNPELLETSRKSREPTGVEENKTDSLFVLPSRDDATPVRDEPMDAESITFK 
A2      -----SEGFLNPELLETSRKSREPTGVEENKTDSLFVLPSRDDATPVRDEPMDAESITFK 
                                                                     
 
A8      SLDDEDKVELDKNFA---DKKEKKKGKWNEDEEDIFEDRKEELPKESDRRDRKDRRHDDE 
A9      ------------------------------------------------------------ 
A6      E---------SSPK-----TPEKSHDDYLTAKARIM------------------ASQPVI 
A7      ------------------------------------------------------------ 
A3      ------------------------------------------------------------ 
A5      ------------------------------------------------------------ 
A4      SVSDKDKREKDKPKVKSDKTKRKSDGSATAKKDNVLKPSKGPQEKVDGDREKSPRSEPPL 
A1      SVSEKDKRERDKPKAKGDKTKRKNDGSAVSKKENIVKPAKGPQEKVDGERERSPRSEPPI 
A2      SVSEKDKRERDKPKAKGDKTKRKNDGSAVSKKENIVKPAKGPQEKVDGERERSPRSEPPI 
                                                                     
 
A8      DDRKERRHERDSQKIDEQDRKKERKRDRETEAYD-SDKLQAPKTKVKREDKKRDDRKDYE 
A9      --------------------------------------------------------KDYE 
A6      NDTEME-----------------TNVGKENKA----------KSPLSKDRK----KKKKD 
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A7      ------------------------------------------------------------ 
A3      ------------------------------------------------------------ 
A5      ------------------------------------------------------------ 
A4      KKAKEEATKIDSVKPSSSSQKDEKVTGTPRKAHSKSAKEHQEAKPAKDEKV----KKDCS 
A1      KKAKEETPKTDNTKSSSSSQKDEKITGTPRKAHSKSAKEHQETKPVKEEKV----KKDYS 
A2      KKAKEETPKTDNTKSSSSSQKDEKITGTPRKAHSKSAKEHQETKPVKEEKV----KKDYS 
                                                                     
 
A8      RDRERRKDDYEKEKS-------KRKESDRDNEKEKQREKEVEKEHEKDRK------EKRK 
A9      RDRERRKDDYEKEKS-------KRKESDRDNEKEKQREKEVEKEHEKDRK------EKRK 
A6      KDKAERKKNKKDK---------RAKKEKGDRQKKSSSVNRSDSDINNSSLMNESNYK--- 
A7      ------------------------------------------------------------ 
A3      ------------------------------------------------------------ 
A5      ------------------------------------------------------------ 
A4      KDIKSEKPASKDEKAKKP-EKNKLLDSKGEKRKRKTEEKSVDKDFESSSM-KISKVEGTE 
A1      KDVKSEKLTTKEEKAKKPNEKNKPLDNKGEKRKRKTEEKGVDKDFESSSM-KISKLEVTE 
A2      KDVKSEKLTTKEEKAKKPNEKNKPLDNKGEKRKRKTEEKGVDKDFESSSM-KISKLEVTE 
                                                                     
 
A8      IVEKESEKPRKSVHERMQKADSSTSSSSRTTTAPSLERKPVSFTVA-SSKPTTNIRV--- 
A9      IVEKESEKPRKSVHERMQKADSSTSSSSRTTTAPSLERKPVSFTVA-SSKPTTNIRV--- 
A6      VLS---PRA-----------------------------------------QSPSIEINAA 
A7      ------------------------------------------------------------ 
A3      ------------------------------------------------------------ 
A5      ------------------------------------------------------------ 
A4      IVK---PSPKRKMEGDVE----------------KLERTPEKDKIASSTTPAKKIKLNRE 
A1      IVK---PSPKRKMEPDTE----------------KMDRTPEKDKISL-SAPAKKIKLNRE 
A2      IVK---PSPKRKMEPDTE----------------KMDRTPEKDKISL-SAPAKKIKLNRE 
                                                                     
 
A8      ---------------------------------------------------RQYSSSSST 
A9      ---------------------------------------------------RQYSSSSST 
A6      ---QL------------------------------------------------------- 
A7      ------------------------------------------------------------ 
A3      ------------------------------------------------------------ 
A5      ------------------------------------------------------------ 
A4      TGKKIGNAENASTTKEPSEKLESTSSKIKQEKVKGKAKRKVAGSEGSSSTLVDYTSTSST 
A1      TGKKIGSTENISNTKEPSEKLESTSSKVKQEKVKGKVRRKVTGTEGSSSTLVDYTSTSST 
A2      TGKKIGSTENISNTKEPSEKLESTSSKVKQEKVKGKVRRKVTGTEGSSSTLVDYTSTSST 
                                                                     
 
A8      KEQEDEERSKRDRRKKDETDVESIGEKEKKSSSRKVPKESVDVKHKSTKIKFDL------ 
A9      KEQEDEERSKRDRRKKDETDVESIGEKEKKSSSRKVPKESVDVKHKSTKIKFDL------ 
A6      --SPT-----HNATENVNPKSHSILTVGAASDDNLGPRSKLSEANSVNLSKWEIDENILG 
A7      ------------------------------------------------------------ 
A3      ------------------------------------------------------------ 
A5      ------------------------------------------------------------ 
A4      GGSPV-----RKSEEKTDTKRTVIKTMEEYNNDNTAPAEDVIIMIQVPQSKWDKDDFESE 
A1      GGSPV-----RKSEEKTDTKRTVIKTMEEYNNDNTAPAEDVIIMIQVPQSKWDKDDFESE 
A2      GGSPV-----RKSEEKTDTKRTVIKTMEEYNNDNTAPAEDVIIMIQVPQSKWDKDDFESE 
                                                                     
 
A8      ------------------------------------------------------------ 
A9      ------------------------------------------------------------ 
A6      LEDSSKK-AAGASDDPSEITSDVLRKAENAIFAKAINAIRPMEFQ---------VII--- 
A7      ------------------------------------------------------------ 
A3      ------------------------------------------------------------ 
A5      ------------------------------------------------------------ 
A4      EEDVKTTQPIQSVGKPSSIIKNVTTKPSATAKYTEKESEQPEKLQKLPKEASHELMQHEL 
A1      EEDVKSTQPISSVGKPASVIKNVSTKPSNIVKYPEKESEPSEKIQKFTKDVSHEIIQHEV 
A2      EEDVKSTQPISSVGKPASVIKNVSTKPSNIVKYPEKESEPSEKIQKFTKDVSHEIIQHEV 
                                                                     
 
A8      -------------------------------------------------------L---- 
A9      ------------------------------------------------------------ 
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A6      NS--------KDNSKDRSVVRSDKDRSSSPRRNNSS----RSVKDRLGTK-----ISN-- 
A7      ------------------------------------------------------------ 
A3      ------------------------------------------------------------ 
A5      ------------------------------------------------------------ 
A4      RSSKGSASSEKGRAKDREHSGSEKDNP--DKRKSGAQPDKESTVDRLSEQGHFKTLSQSS 
A1      KSSKNSASSEKGKTKDRDYSVLEKENP--EKRKNSTQPEKESNLDRLNEQGNFKSLSQSS 
A2      KSSKNSASSEKGKTKDRDYSVLEKENP--EKRKNSTQPEKESNLDRLNEQGNFKSLSQSS 
                                                                     
 
A8      ------------------------------------------------------------ 
A9      ------------------------------------------------------------ 
A6      DRSRSRDKSKGRRRAARSSDDDANRGRSDRH--------GSRKRDNR---SRDRAAPSE- 
A7      ------------------------------------------------------------ 
A3      ------------------------------------------------------------ 
A5      ------------------------------------------------------------ 
A4      KETRTSEKHES---VRGSSNKDFTPGRDKKVDYDSRDYSSSKRRDERGELARRKDSPPRG 
A1      KEARTSDKHDS---TRASSNKDFTPNRDKKTDYDTREYSSSKRRDEKNELTRRKDSPSRN 
A2      KEARTSDKHDS---TRASSNKDFTPNRDKKTDYDTREYSSSKRRDEKNELTRRKDSPSRN 
                                                                     
 
A8      ------------------------------------------------------------ 
A9      ------------------------------------------------------------ 
A6      ----------KRQERSYK----------RSSPEDDKLRRQNKEQSESKHG-----KHDQN 
A7      ------------------------------------------------------------ 
A3      ------------------------------------------------------------ 
A5      ------------------------------------------------------------ 
A4      KESLSGQKSKLREERDLPKKGAE-SKKSNSSPPRDKKPHDHKAPYETKRPCEETKPVDKN 
A1      KDSASGQKNKPREERDLPKKGTGDSKKSNSSPSRDRKPHDHKATYDTKRPNEETKSVDKN 
A2      KDSASGQKNKPREERDLPKKGTGDSKKSNSSPSRDRKPHDHKATYDTKRPNEETKSVDKN 
                                                                     
 
A8      ------------------------------------------------------------ 
A9      ------------------------------------------------------------ 
A6      NSDDSDRRA--AKNTKSSDSRVVSSVTAVVAPPKPCRPDNPFRKFVD------------- 
A7      ------------------------------------------------------------ 
A3      ------------------------------------------------------------ 
A5      ------------------------------------------------------------ 
A4      SGKEREKHAAEARNGKESSG---GKLPCIPNPPDPPMEKELAAGQVEKSAVKPKPQLSHS 
A1      PCKDREKHVLEARNNKESSG---NKLLYILNPPETQVEKEQITGQIDKSTVKPKPQLSHS 
A2      PCKDREKHVLEARNNKESSG---NKLLYILNPPETQVEKEQITGQIDKSTVKPKPQLSHS 
                                                                     
 
A8      ------------------------------------------------------------ 
A9      ------------------------------------------------------------ 
A6      ----------------------TSSSSSLVVKYDNTI------------QKE------GA 
A7      ------------------------------------------------------------ 
A3      ------------------------------------------------------------ 
A5      ------------------------------------------------------------ 
A4      SRLSSDLTRETDEAAFEPDYNESDSESNVSVKEEEAVASISKDLKEKTTEKAKESLTVAT 
A1      SRLSSDLTRETDEAAFEPDYNESDSESNVSVKEEESSGNISKDLKDKIVEKAKESLDTAA 
A2      SRLSSDLTRETDEAAFEPDYNESDSESNVSVKEEESSGNISKDLKDKIVEKAKESLDTAA 
                                                                     
 
A8      ------------------------------------------------------------ 
A9      ------------------------------------------------------------ 
A6      SSDNGMEHRKQR--------------DKKLKKHSK-YSSTDSLKSEKRKDPKSKKKSKIL 
A7      ------------------------------------------------------------ 
A3      ------------------------------------------------------------ 
A5      ------------------------------------------------------------ 
A4      ASQPGADRSQSQSSPSVSPSRSHSPSGSQTRSHSSSASSAGSQDSKKKKKKKEKKKHKKH 
A1      VVQVGISRNQSHSSPSVSPSRSHSPSGSQTRSHSSSASSAESQDSKKKKKKKEKKKHKKH 
A2      VVQVGISRNQSHSSPSVSPSRSHSPSGSQTRSHSSSASSAESQDSKKKKKKKEKKKHKKH 
                                                                     
 
A8      --------------------------------------------------- 
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A9      --------------------------------------------------- 
A6      KKKKKSKK------------------------------------------- 
A7      --------------------------------------------------- 
A3      --------------------------------------------------- 
A5      --------------------------------------------------- 
A4      KKHKKHKKHAGADGDVEKSQKHKHKKKKAKKNKDKE--KEKDDQKVRSVTV 
A1      KKHKKHKKHAGTEVELEKSQKHKHKKKKSKKNKDKEKEKEKDDQKVKSVTV 
A2      KKHKKHKKHAGTEVELEKSQKHKHKKKKSKKNKDKEKEKEKDDQKVKSVTV 
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Appendix E: Survival analysis data 
 
 
 
Statistix 10 
 
Kaplan-Meier Product-Limit Survival Distribution 
Time Variable:  Days   
Event Variable: Death  
Group Variable: Group  
 
Group = Co-treatment 
             Cen-   At     Lower               Upper  
Time  Died  sored  Risk   95% C.I.    S(t)    95% C.I.   SE S(t)    H(t)  
   3    22     0    100    0 .7007    0.7800    0.8430    0.0414    0.2485  
   6     2     0     78    0.6690    0.7600    0.8323    0.0427    0.2744  
   9     5     0     76    0.6180    0.7100    0.7875    0.0454    0.3425  
  12     7    64     71    0.5474    0.6400    0.7233    0.048 0    0.4463 
 
Group = irinotecan 
             Cen-   At     Lower               Upper  
Time  Died  sored  Risk   95% C.I.    S(t)    95% C.I.   SE S(t)    H(t)  
   3    25     0    100    0.6702    0.7500    0.8158    0.0433    0.2877  
   6     2     0     75    0.6370    0.7300    0.8064    0.0444    0.3147  
   9     5     0     73    0.5869    0.6800    0.7607    0.0466    0.3857  
  12     2    66     68    0.5643    0.6600    0.7442    0.0474    0.4155  
 
Group = methyl pyruvate 
             Cen-   At     Lower               Upper  
Time  Died  sored  Risk   95% C.I.    S(t)    95% C.I.   SE S(t)    H(t)  
   3    15     0    100    0.7745    0.8500    0.9034    0.0357    0.1625  
   6     3     0     85    0.7350    0.8200    0.8821    0.0384    0.1985  
   9     2     0     82    0.7124    0.8000    0.8660    0.0400    0.2231  
  12     2    78     80    0.6905    0.7800    0.8492    0.0414    0.2485  
 
Group = untreated 
             Cen-   At     Lower               Upper  
Time  Died  sored  Risk   95% C.I.    S(t)    95% C.I.   SE S(t)    H(t)  
   3     7     0    100    0.8655    0.9300    0.9648    0.0255    0.0726  
   6     4     0     93    0.8157    0.8900    0.9367    0.0313    0.1165  
   9     2     0     89    0.7912    0.8700    0.9220    0.0336    0.13 93 
  12     0    87     87 
 
 
Kaplan-Meier Product-Limit Survival Distribution  
Time Variable:  days   
Event Variable: death  
Group Variable: group  
 
Group = Co-treatment 
             Cen-   At     Lower               Upper  
Time  Died  sored  Risk   95% C.I.    S(t)    95% C.I.   SE S(t)    H(t)  
   3     0    10     30 
   6     2     8     20    0.7117    0.9000    0.9704    0.0671    0.1054  
   9     8     2     10    0.100 8    0.1800    0.3006    0.1146    1.7148  
 
group = irinotecan 
             Cen-   At     Lower               Upper  
Time  Died  sored  Risk   95% C.I.    S(t)    95% C.I.   SE S(t)    H(t)  
   3     1     9     30    0.8366    0.9667    0.9939    0.0328    0 .0339 
   6     1     9     20    0.7324    0.9183    0.9788    0.0565    0.0852  
   9     8     2     10    0.1029    0.1837    0.3061    0.1167    1.6946  
 
group = Methyl-Pyruvate 
             Cen-   At     Lower               Upper  
Time  Died  sored  Risk   95% C.I.     S(t)    95% C.I.   SE S(t)    H(t)  
   3     4     6     30    0.7165    0.8667    0.9435    0.0621    0.1431  
   6     1     9     20    0.6315    0.8233    0.9269    0.0725    0.1944  
   9     5     5     10    0.2415    0.4117    0.6060    0.1351    0. 8875 
 
group = untreated 
             Cen-   At     Lower               Upper  
Time  Died  sored  Risk   95% C.I.    S(t)    95% C.I.   SE S(t)    H(t)  
   3     2     8     30    0.7934    0.9333    0.9808    0.0455    0.0690  
   6     4     6     20    0.5586    0.7467    0.8728    0.0911    0.2921  
   9     3     7     10    0.3146    0.5227    0.7232    0.1256    0.6488  
 
